



维亚生物科技控股集团
VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

Stock Code: 1873



2020
INTERIM
REPORT



CONTENTS

2	Corporate Information
4	Management Discussion and Analysis
17	Supplementary Information
36	Independent Review Report
37	Interim Condensed Consolidated Statement of Profit or Loss
38	Interim Condensed Consolidated Statement of Comprehensive Income
39	Interim Condensed Consolidated Statement of Financial Position
41	Interim Condensed Consolidated Statement of Changes in Equity
42	Interim Condensed Consolidated Statement of Cash Flows
45	Notes to Interim Condensed Consolidated Financial Information
76	Definitions

Corporate Information

BOARD OF DIRECTORS

Executive Directors

Mr. MAO Chen Cheney (*Chairman of the Board*)
Mr. WU Ying
Mr. HUA Fengmao
Mr. REN Delin

Non-executive Directors

Ms. MAO Jun
Ms. SUN Yanyan

Independent Non-executive Directors

Mr. FU Lei
Ms. LI Xiangrong
Mr. WANG Haiguang

AUDIT COMMITTEE

Ms. LI Xiangrong (*Chairman*)
Mr. WANG Haiguang
Mr. FU Lei

REMUNERATION COMMITTEE

Ms. LI Xiangrong (*Chairman*)
Mr. WANG Haiguang
Mr. FU Lei

NOMINATION COMMITTEE

Mr. MAO Chen Cheney (*Chairman*)
Mr. WANG Haiguang
Mr. FU Lei

JOINT COMPANY SECRETARIES

Ms. FEI Xiaoyu
Ms. CHAU Hing Ling (*a fellow member of the Chartered Governance Institute (formerly known as the Institute of Chartered Secretaries and Administrators) and the Hong Kong Institute of Chartered Secretaries*)

AUTHORIZED REPRESENTATIVES

Mr. HUA Fengmao
Ms. CHAU Hing Ling (*a fellow member of the Chartered Governance Institute (formerly known as the Institute of Chartered Secretaries and Administrators) and the Hong Kong Institute of Chartered Secretaries*)

AUDITOR

Ernst & Young
Certified Public Accountant

LEGAL ADVISERS

O'Melveny & Myers (*as to Hong Kong law*)
Maples and Calder (Hong Kong) LLP
(*as to Cayman Islands laws*)

COMPLIANCE ADVISER

Guotai Junan Capital Limited

PRINCIPAL BANKS

Agricultural Bank of China Shanghai Branch
The Hongkong and Shanghai Banking Corporation Limited
Bank of China (Hong Kong) Limited
JP Morgan Chase Bank, N.A.
Citibank N.A., Hong Kong Branch

REGISTERED OFFICE

PO Box 309
Ugland House
Grand Cayman, KY1-1104
Cayman Islands

CORPORATE HEADQUARTERS

334 Aidisheng Road
Zhangjiang High-Tech Park
Pudong New District
Shanghai, PRC

**PRINCIPAL PLACE OF BUSINESS IN
HONG KONG**

Room 1901, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

PRINCIPAL SHARE REGISTRAR

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall
Cricket Square
Grand Cayman, KY1-1102
Cayman Islands

**HONG KONG BRANCH SHARE
REGISTRAR AND TRANSFER OFFICE**

Tricor Investor Services Limited
Level 54, Hopewell Centre
183 Queen's Road East
Hong Kong

STOCK CODE

1873

COMPANY'S WEBSITE

www.vivabiotech.com

LISTING DATE

May 9, 2019

Management Discussion and Analysis

BUSINESS REVIEW

During the first half of 2020, the COVID-19 pandemic struck a blow to domestic and global health and economic development, triggering challenges of different severity to various industries. Closely related to the health of mankind, the biopharmaceutical sector has drawn heightened attention and expectations from society and capital market. Meanwhile, after a temporary adjustment amid the COVID-19 pandemic, China's CRO industry delivered upward growth momentum. The Group actively implemented pandemic containment measures to seek opportunities behind such crisis and accelerate the integration of research and development (“R&D”) and production service chain of new drug industry, thereby achieving further synergistic effect between the cash-for-service (CFS) model and equity-for-service (EFS) model.

During the Reporting Period, our revenue increased significantly to RMB197.6 million from RMB142.3 million for the corresponding period last year, representing a year-on-year increase of 38.9%. Our adjusted net profit increased to RMB123.7 million from RMB98.6 million for the corresponding period last year, representing a year-on-year increase of 25.5%. As of June 30, 2020, our backlog amount reached approximately RMB493 million, representing a significant increase of approximately 138.2% from the same period last year, including approximately RMB325 million under the CFS model, representing an increase of approximately 118% from the same period last year; and approximately RMB168 million under the EFS model, representing an increase of approximately 190% from the same period last year.

CASH-FOR-SERVICE (CFS) BUSINESS

Leveraging our globally leading technology platform and sound reputation, the Company vigorously expanded the international and domestic markets during the COVID-19 pandemic, leading to a substantially enlarged and more diverse customer base. As of June 30, 2020, the Company had provided drug discovery services to an aggregate of over 495 biotechnology and pharmaceutical customers worldwide, delivered over 17,000 protein complex structures and conducted research into more than 1,300 independent drug targets. During the Reporting Period, revenue from the CFS segment increased to RMB154.0 million from RMB105.4 million for the corresponding period last year, representing a year-on-year increase of 46.1%. The primary reason behind such increase was a rise in the number of customers and orders secured from customers. Total revenue from the top ten customers increased from RMB64.7 million for the six months ended June 30, 2019 to RMB82.1 million for the six months ended June 30, 2020, while total revenue contributed by top ten customers as a percentage of the Group's total revenue decreased from 45.5% to 41.5%, indicating a continuously optimized customer structure.

EQUITY-FOR-SERVICE (EFS) BUSINESS

During the first half of 2020, we extensively explored business opportunities around the globe on an on-going basis and established long-term cooperation relations and recommendation systems with near 60 universities, research transformation centers and investment institutions world-wide. During the Reporting Period, the Company reviewed a total of over 425 projects globally, added 10 startups to our portfolio companies, made additional investment in 3 existing portfolio companies, and was in negotiation for incubation and investment in 3 new companies. The Company had a total of 56 portfolio start-ups with an average agreed shareholding¹ of 21.78%. Details are as follows:

No.	Company Name	Type	Time of investment/incubation agreement	Indications/Primary Technology/Business	Shareholding % received as at the date of this report
1	Blue Oak Pharmaceuticals, Inc.	EFS	2020/02	Discovering novel multi-target pathways to help patients with neurological disorders, focusing on systems neurobiology and brain circuitry.	3.15%
2	Regenacy Pharmaceuticals, Inc.	Strategic investment	2020/03	Developing innovative treatment of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy.	1.67%
3	Elgia Therapeutics, Inc.	EFS	2020/04	Focusing on the discovery and development of specific Caspase inhibitors for nonalcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) therapy and other inflammatory conditions.	9.68%
4	Phenomic AI Inc.	EFS	2020/05	Developing therapeutic antibodies targeting colorectal cancer.	5.03%

¹ The agreed shareholding takes into account shareholding which the Company will acquire upon fulfilment of service milestones and other milestone events. The figure does not take into account investments where the agreed quantity of shareholding to be converted from such convertible bond investments are not determined as at the date of this report.

Management Discussion and Analysis

No.	Company Name	Type	Time of investment/incubation agreement	Indications/Primary Technology/Business	Shareholding % received as at the date of this report
5	Vincere Biosciences, Inc.	EFS	2020/06	Developing therapeutics targeting mitochondrial pathways for brain disorders particularly in neuro degenerative diseases.	0%*
6	NERIO Therapeutics, Inc.	Strategic investment	2020/06	Developing allosteric/uncompetitive phosphatase inhibitors for several protein tyrosine phosphatase (PTP)s.	3.79%
7	Sisu Pharma, Inc.	EFS	2020/06	Focusing on the development of HSF1 inhibitor for the hormone treatment resistant prostate cancer.	4.98%
8	Focus-X Therapeutics, Inc.	EFS	2020/06	Focusing on the development of peptide receptor radionuclide therapy (PRRT).	0%*
9	Triumvira Immunologics Inc.	Strategic investment	2020/06	Developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.	0%*
10	QurClear LLC	Strategic investment	2020/06	QurClear is a legal entity for holding shares of EnClear Therapies, Inc. Enclear Therapies is developing an equipment to filter toxic protein accumulated in brain and spinal cord to cure amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP) patients with C9orf72 mutation.	3.82%**

* pending agreed service milestones, closing of transaction or conversion of convertible instruments (as the case may be) to receive shareholding interest in relevant incubation portfolio company.

** percentage of the units

Management Discussion and Analysis

None of these investments constituted discloseable transaction under chapter 14 of the Listing Rules.

We continue to attract top ranking scientists from the PRC and overseas to join as our business partners. As of June 30, 2020, our business partners increased to 30, who have attained remarkable achievements in their academic and drug discovery fields. In view of the COVID-19 pandemic, Viva BioInnovator launched on-line Demo Day activities to build a communication platform cross regions and time zones for portfolio companies to interact with investment institutions and pharmaceutical enterprises. We also actively conducted post-investment management to facilitate incubated companies to advance R&D progress, introduce talents, optimize product pipeline development strategies and coordinate fund-raising resources.

TECHNOLOGY PLATFORM, AND FACILITIES

During the first half of 2020, the Company's R&D investment totaled RMB22.3 million, primarily used for introduction of new technology platform such as Cryo-EM, Computational Chemistry and HDX-MS. In addition, the Company also actively mapped out in the antibody macromolecules field and set up CMC process development team, so as to expand and satisfy customers' needs at different R&D stages.

To better meet the Company's requirements arising from rapid business development, the Company acquired the property with a site area of 7,576 square meters located on Faladi Road, Pudong, Shanghai in February 2020. In April, Viva Biotech Chengdu New Drug Incubation and Production R&D Center with a site area of 33,607 square meters commenced construction. Such efforts will accelerate the realization of business strategies, save rental expenses and provide the Company with stable R&D, manufacturing and operation premise.

FINANCING

On February 11, 2020, Viva Incubator Investment Management Limited (“**Viva Incubator HK**”), a wholly-owned subsidiary of the Company, issued US\$180 million convertible bonds due 2025 guaranteed by the Company (the “**2025 Convertible Bonds**”), proceeds from which are primarily used for business expansion and integration towards the downstream of the industry chain and daily business operation of the Company. Such financing activity provided the Company with sound capital support to accelerate the realization of its strategic development goals.

Management Discussion and Analysis

FUTURE STRATEGIES AND OUTLOOK

Positioning at the source of early-stage discovery of innovative drugs with technology platform, flow of traffic and talent advantages, the Company is speeding up the construction of a comprehensive and one-stop drug service platform, which is designated to provide customers with more comprehensive drug development services. Strategic integration with Zhejiang Langhua Pharmaceutical Co., Ltd. will bring together the synergistic effect of both parties in the R&D, design and manufacturing fields of global pharmaceutical markets, which is of great strategic significance to the Company in terms of vertical integration along the industrial chain and expansion into the CDMO (contract development and manufacturing organization) business.

In the future, the Company will continue to strengthen the technology advantages, enhance operation efficiency, introduce more talented scientists and technologies, improve capacity of the incubation platforms, strengthen loyalty between existing customers and portfolio companies and proactively conduct industrial integration, in a bid to establish an open and cooperative platform targeting at global biopharmaceutical innovators and build an ecosystem featuring cooperation and mutual benefits.

DISCUSSION OF RESULT OF OPERATION

Revenue

The Group's revenue in the Reporting Period was approximately RMB197.6 million, representing an increase of 38.9% as compared to approximately RMB142.3 million in the corresponding period last year, primarily reflecting the Group's business growth.

Management Discussion and Analysis

During the Reporting Period, revenue generated from the Group’s CFS and EFS models reflected revenue generated from services to our non-investee and investee customers, respectively. The following table sets forth a breakdown of the Group’s revenue by respective charge models during the Reporting Period and the corresponding period last year.

	For the six months ended June 30,	
	2020	2019
	RMB’000	RMB’000
	(Unaudited)	(Unaudited)
Revenue from services to non-investees (CFS model):		
– Full-time-equivalent (“ FTE ”)	118,102	79,781
– Fee-for-service (“ FFS ”)	35,908	25,620
	154,010	105,401
Revenue from services to investees (EFS model):		
– FTE	13,924	12,330
– FFS	867	270
– Service-for-equity (“ SFE ”)	28,756	24,340
	43,547	36,940
	197,557	142,341

Management Discussion and Analysis

While the Group's operations are located in China, it has a global customer base with a majority of our customers located in the USA. An analysis of the Group's revenue from customers, analyzed by their respective country/region of operation, is detailed below:

	For the six months ended June 30,	
	2020	2019
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Revenue		
– USA	164,636	119,545
– PRC	26,989	22,135
– Europe	2,281	391
– Other Countries and Regions	3,651	270
	197,557	142,341

The increase of revenue in the Reporting Period as compared to the corresponding period last year was primarily due to an increase in the revenue of the Group's customers headquartered in the USA and China. This was mainly due to increases in the number of customers as well as customer orders.

Cost of Services

Cost of services primarily consists of direct labor costs, cost of materials and overhead. Direct labor costs primarily consist of salaries, bonus, welfare, social security costs and share-based compensation for our R&D talents, excluding the costs allocated to research and development expenses, as well as those capitalized in contract costs. Cost of services in the Reporting Period was approximately RMB97.4 million, representing an increase of 38.2% as compared to approximately RMB70.5 million in the corresponding period last year. The increase was in line with the Group's business growth.

Gross Profit and Gross Profit Margin

During the Reporting Period, the Group's gross profit was approximately RMB100.1 million, representing an increase of 39.2% as compared to approximately RMB71.9 million in the corresponding period last year. The increase was in line with the Group's business growth. Gross margin was 50.7% for the Reporting Period, as compared to 50.5% for the corresponding period last year.

Management Discussion and Analysis

Other Income and Gains

Other income and gains consist primarily of interest income, government grants and subsidies, net foreign exchange gain, gain on deemed disposal of interests in an associate, gain on repurchase of convertible bonds gain on derivative financial instruments and gain on disposal of right-of-use assets. During the Reporting Period, the Group recorded a gain of approximately RMB27.2 million, representing a decrease of 20.5% as compared to approximately RMB34.2 million in the corresponding period last year. The decrease was primarily due to an approximately RMB9.9 million decrease in gain on deemed disposal of interests in an associate.

Selling and Distribution Expenses

Selling and distribution expenses primarily consist of staff cost, travelling expenses and others. During the Reporting Period, the Group's selling and distribution expenses were approximately RMB2.0 million, representing a slight increase of by 11.1% as compared to approximately RMB1.8 million in the corresponding period last year. The increase was primarily due to an increase in business development fee.

Administrative Expenses

Administrative expenses primarily consist of administrative staff costs, audit and consultancy fees, office administration expense, rental, depreciation, travelling and transportation expenses and others. During the Reporting Period, the Group's administrative expenses were approximately RMB37.0 million, representing an increase of 65.2% as compared to approximately RMB22.4 million in the corresponding period last year. The increase was primarily due to the expansion of the Group's incubation team, together with an approximately RMB5.1 million increase in convertible bonds transaction costs relating to the embedded derivative components.

Research and Development Expenses

R&D expenses mainly consist of labor costs, cost of materials, overhead costs and fees paid to third parties that conduct certain R&D activities on our behalf. During the Reporting Period, the Group's R&D expenses were approximately RMB22.3 million, representing an increase of 42.9% as compared to approximately RMB15.6 million in the corresponding period last year. The increase was primarily due to the introduction of new technology platform such as Cryo-EM, Computational Chemistry and HDX-MS.

Fair Value Gain on Financial Assets at Fair Value through Profit or Loss ("FVTPL")

Fair value gain on FVTPL mainly consists of fair value gains from financial products issued by banks and the gains from the fair value change of the equity interests in the Group's incubation portfolio companies.

Management Discussion and Analysis

The Group's EFS model features sharing of the upside of our customers' IP values, which is primarily reflected by the gains from the fair value change of the equity interest in the Group's incubation portfolio companies. Such fair value gains are recorded as fair value gain on financial assets at FVTPL in the Group's financial statements. Except for Proviva Therapeutics, Inc, no individual equity interests in the Group's incubation portfolio companies accounted for more than 5% of the Group's total assets.

The Group recorded gains arising from fair value change of the equity interests in the Group's incubation portfolio companies designated at FVTPL of approximately RMB54.7 million for the Reporting Period, primarily reflecting the increase in the fair value of the Group's equity interest in three incubation portfolio companies, VersaChem, Inc., Mediar Therapeutics, Inc. and Anji Pharmaceuticals, Inc., as compared to approximately RMB48.2 million for the corresponding period last year, primarily reflecting the increase in fair value of the Group's equity interest in three incubation portfolio companies, Anji Pharmaceuticals, Inc., Weimou Biotech (Shanghai) Ltd. and Liangzhun (Shanghai) Industrial Co., Ltd.

The Group recorded a fair value gain from financial products issued by banks of approximately RMB12.0 million, as compared to nil in the corresponding period last year.

Impairment Losses on Financial Assets, Net

Impairment losses under expected credit model, net of reversal reflects impairment loss on trade receivables. The Group recorded impairment losses of approximately RMB0.4 million for the Reporting Period, representing a decrease of 69.2% as compared to approximately RMB1.3 million of impairment losses for the corresponding period last year.

Finance Costs

Finance cost primarily consists of interest on convertible bonds, interest on lease liabilities and interest expenses on loans from banks. For the Reporting Period, the Group's finance cost was approximately RMB38.6 million, representing an increase of 4,188.9%, as compared to approximately RMB0.9 million for the corresponding period last year. The increase was mainly due to an approximately RMB37.8 million increase in interest of the debt components of the convertible bonds.

Share of Loss of a Joint Venture

For the Reporting Period, the Group recorded share of loss of a joint venture of approximately RMB0.3 million, as compared to approximately RMB0.9 million for the corresponding period last year. The decrease primarily represented the Group's decreased share of loss in one of its incubation portfolio companies, Jiaxing Youbo Biotech Co., Ltd.

Management Discussion and Analysis

Fair Value Loss on Financial Liabilities at FVTPL

Fair value loss on financial liabilities at FVTPL represents changes in fair value of the embedded derivative components of the convertible bonds. For the Reporting Period, the Group recorded fair value loss on financial liabilities at FVTPL of approximately RMB615.5 million, as compared to approximately RMB34.2 million for the corresponding period last year, which represents changes in fair value of the series B convertible redeemable preferred shares (the “**Series B Preferred Shares**”) in connection with the Company’s pre-IPO financing.

Income Tax Expense

The Group’s income tax expense was approximately RMB7.9 million, representing a decrease of 37.8% from approximately RMB12.7 million for the corresponding period last year, primarily due to a decrease in fair value gain which subject to tax.

Net Profit and Net Profit Margin

As a result of the foregoing, the Group’s net loss for the Reporting Period was approximately RMB530.3 million, as compared to a net profit of RMB46.5 million for the corresponding period last year. The decrease was primarily due to increase in fair value loss of the embedded derivative components of the convertible bonds.

The adjusted non-IFRS net profit of the Group increased 25.5% to approximately RMB123.7 million for the Reporting Period from approximately RMB98.6 million for the corresponding period last year. The adjusted non-IFRS net profit margin of the Group for the Reporting Period was 62.6%, compared to 69.3% for the corresponding period last year. The lower adjusted Non-IFRS net profit margin of the Group for the Reporting Period was primarily due to the rapid growth in our revenue, and the increase in the administrative expenses.

Liquidity and Financial Resources

As at June 30, 2020, the Group’s total cash and cash equivalents amounted to approximately RMB1,521.3 million, representing an increase of 68.3% as compared to approximately RMB904.1 million as at December 31, 2019. Such increase was primarily attributable to the proceeds from the 2025 Convertible Bonds. The Group maintains a strong cash position to meet potential needs for business expansion and development.

As at June 30, 2020, current assets of the Group amounted to approximately RMB2,174.1 million, including a cash and cash equivalents of approximately RMB1,521.3 million. Current liabilities of the Group amounted to approximately RMB134.2 million, including bank borrowings of approximately RMB15.9 million.

Management Discussion and Analysis

As at June 30, 2020, the gearing ratio, calculated as total liabilities over total assets, was 42.4%, as compared with 6.4% as at December 31, 2019. The higher ratio is due primarily to the liabilities of 2025 Convertible Bonds increased RMB1,224.7 million.

As at June 30, 2020, the Group had approximately RMB17.0 million of secured and unguaranteed bank loans. Of the total borrowing, approximately RMB15.9 million will be due within one year; approximately RMB1.1 million will be due in more than one year. As at June 30, 2020, the Group has HK\$53.2 million (equivalent to RMB48.6 million) unutilized banking facilities. The Group intends to finance the expansion, investments and business operations with proceeds from the Global Offering, 2025 Convertible Bonds, bank loans and internal resources.

Significant Investment, Material Acquisitions and Disposals

In March 2020, Viva Biotech Shanghai, an indirect wholly-owned subsidiary of the Company, acquired 100% of equity interest of Shanghai Shenyu Wires Co., Ltd from its original shareholders, at a consideration of RMB120.0 million.

Proviva Therapeutics, Inc (“**Proviva**”), one of our incubation portfolio company constituted a significant investment of the Group. On June 28, 2019, the Group entered into an agreement to acquire 35% shareholding interest of the fully diluted equity of Proviva for approximately US\$12,560,753 (in a combination of US\$10,000,000 cash and US\$2,560,753 equity-for-service business). On December 31, 2019, the Group disposed of 4% shareholding interest of its 35% shareholding interest in the fully diluted equity of Proviva for a consideration of US\$4,000,000. As of June 30, 2020, the Group’s investment in Proviva was recorded as a financial asset at fair value of approximately RMB221,284,000.

Proviva is a company with a focus on the research and development of a pro-cytokine (Zitokine) fusion protein platform, for the treatment of cancer and infectious diseases. The Company’s decision on investment in Proviva is mainly based on the founder’s years of experience in new drug research and development, the innovation of the platform, its indications and broad market prospects. Meanwhile, the technical services required for Proviva’s early-stage research and development are highly synergic with the Company’s leading technology platform. The Company will continue to pay attention to and regularly follow up on its research and development progress and financing needs, provide timely technical services within our capabilities, bridge industrial resources and investors, etc., and assist it in advancing its progress for pre-clinical and clinical trials. Based on the progress of its financing, the Company will continue to evaluate and make reasonable arrangements on partial exit of our equity interest.

Save as disclosed in this report, the Group did not make any significant investments and did not have material acquisitions or disposals of subsidiaries, associates and joint ventures for the six months ended June 30, 2020.

Management Discussion and Analysis

Pledge of Assets

As at June 30, 2020, the building with a carrying amount of approximately RMB5.1 million was pledged to secure borrowings of the Group. As at June 30, 2020, a bank deposit for HK\$70.0 million (or its equivalent in other foreign currencies) is placed with the bank to secure a bank facility of HK\$70.0 million (or its equivalent in US\$/CNY).

Capital Expenditure

For the Reporting Period, the Group's capital expenditure amounted to approximately RMB70.2 million, which was mainly used for construction of facilities and equipment purchases, as compared to approximately RMB15.1 million for the corresponding period last year. The Group funded its capital expenditure by using cash flow generated from its operations and financing.

Contingent Liabilities

The Group had no material contingent liabilities as at June 30, 2020.

Future Plan for Material Investment and Capital Assets

Save as disclosed in this interim report, Prospectus and other announcement (including but not limited to the Company's announcement dated August 9, 2020 on acquisition of equity interest of Zhejiang Langhua Pharmaceutical Co., Ltd., and the Company's announcement dated July 1, 2020, the Company announced that Viva Biotech Shanghai had successfully entered into a bid for the land use right of the property by way of internet auction through taobao.com (淘寶網) published by the Shanghai Pudong District People's Court (上海市浦東新區人民法院) at a bidding price of RMB392.4 million and obtained the internet auction confirmation on the same day.) published by the Company up to the date of this interim report, there was no plan authorized by the Board for material investments and capital assets for the Reporting Period and up to the date of this interim report.

Currency Risk

Certain entities in our Group have foreign currency sales and purchases, which exposes us to foreign currency risk. In addition, certain entities in our Group also have other payables and receivables which are denominated in currencies other than their respective functional currencies. We recorded a net foreign exchange gain of approximately RMB8.7 million and approximately RMB15.6 million for the Reporting Period and the corresponding period last year, respectively. We are exposed to the foreign currency of U.S. dollars as part of our revenue was generated from sales denominated in U.S. dollars. We purchased various bank foreign exchange wealth management products to hedge against our exposure to currency risk during the Reporting Period. Management will continue to evaluate the Group's foreign exchange risk and take actions as appropriate to minimize the Group's exposure whenever necessary.

Management Discussion and Analysis

EMPLOYEE REMUNERATION AND RELATIONS

As at June 30, 2020, the Group had a total of 798 employee and the total staff costs for the Reporting Period (including directors' emoluments) were RMB86.5 million. Remuneration of our employee is determined with reference to market conditions and individual employees' performance, qualification and experience. In line with the performance of the Group and individual employees, a competitive remuneration package is offered to retain employees, including salaries, discretionary bonuses, share options and contributions to benefit plans (including pensions). During the Reporting Period, the relationship between the Group and our employees has been stable. We had not experienced any strikes or other labor disputes which materially affected our business activities. We provide training programs to employees, including new hire orientation and continuous on-the-job training in order to accelerate the learning progress and improve the knowledge and skill levels of our employees.

Supplementary Information

INTERIM DIVIDEND

The Board has resolved to declare an interim dividend of HK\$0.017 per Share (in an aggregate amount of HK\$32,344,112 as at the date of this report) for the six months ended June 30, 2020 to the Shareholders of the Company whose names appear on the register of members on September 17, 2020. The interim dividend will be paid to such Shareholders on or about October 6, 2020.

CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company was closed from September 15, 2020 to September 17, 2020 (both dates inclusive). In order to qualify for the interim dividend, all transfers, accompanied by the relevant share certificates, must be lodged with the Company's Hong Kong Branch Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration before 4:30 p.m. on September 14, 2020.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

Business objective as stated in the Prospectus	Approximate % of total net proceeds	Planned use of actual net proceeds ⁽¹⁾ <i>RMB' million</i>	Utilized net proceeds up to June 30, 2020 ⁽¹⁾ <i>RMB' million</i>	Proceeds unused ⁽²⁾ <i>RMB' million</i>	Expected timeline for utilizing the remaining balance of net proceeds from the Global Offering ⁽³⁾
Expanding EFS model	30%	365.13	194.08	171.05	Expected to be fully utilized by December 31, 2021
Building up commercial & research manufacturing capabilities and capacities in contract manufacturing organization ("CMO")	30%	365.13	142.74	222.39	Expected to be fully utilized by December 31, 2021
Purchasing laboratory equipment and materials	10%	121.71	121.71	0.00	
Hiring, training and retaining biologics & chemical drug R&D personnel	10%	121.71	121.71	0.00	
Expanding CMO business	10%	121.71	20.00	101.71	Expected to be fully utilized by December 31, 2020
General corporate and working capital	10%	121.71	121.71	0.00	

Supplementary Information

Notes:

- As disclosed in the Prospectus, the estimated net proceeds from the listing, after deduction of the underwriting fees and expenses paid by the Company in connection therewith were approximately HK\$1,231.7 million. The actual net proceeds received by the Company were approximately RMB1,217.1 million. The Company intends to adjust the difference between the estimated and actual net proceeds to each business objective in the same proportion as the original funds applied as shown in the Prospectus.
- As at June 30, 2020, net proceeds not yet utilized were deposited with certain licensed banks in Hong Kong or the PRC.
- The Company intends to use the remaining net proceeds in the coming years in accordance with the purpose set out in the Prospectus, the Company will continue to evaluate the Group's business objectives and will change or modify the plans against the changing market conditions to suit the business growth of the Group. We will issue an appropriate announcement if there is any material change to the above proposed use of proceeds.

USE OF PROCEEDS FROM THE 2025 CONVERTIBLE BONDS

On February 11, 2020, Viva Incubator HK, an indirectly wholly-owned subsidiary of the Company, issued the 2025 Convertible Bonds in an aggregate principal amount of US\$180.0 million, which was guaranteed by the Company. The 2025 Convertible Bonds may initially be converted into 243,493,107 Shares of the Company upon full conversion at the initial conversion price of HK\$5.7456 per Share (subject to the adjustment mechanism as set out therein). The closing price of the Shares was HK\$4.56 on January 22, 2020, being the date of the initial announcement of the proposed 2025 Convertible Bonds issuance. The 2025 Convertible Bonds were offered to no less than six independent placees (who are independent individual, corporate and/or institutional investors).

The net proceeds, after deducting the transaction costs of US\$2.6 million (equivalent to RMB18.3 million), were US\$177.4 million (equivalent to RMB1,256.0 million), and had been utilized as follows as at June 30, 2020:

Business objective as stated in the Offering Circular	Percentage of total net proceeds	Planned use of actual net proceeds <i>RMB' million</i>	Actual use of net proceeds during the period from the issuing date to June 30, 2020 <i>RMB' million</i>	Proceeds unused ⁽¹⁾ <i>RMB' million</i>	Expected timeline for utilizing the remaining balance of net proceeds from the 2025 Convertible Bonds ⁽²⁾
Business development and expansion	70%	879.19	27.27	851.92	Expected to be fully utilized by December 31, 2022
Working capital and general corporate purposes	30%	376.80	6.50	370.30	Expected to be fully utilized by December 31, 2021

Notes:

1. As at June 30, 2020, net proceeds not yet utilized were deposited with certain licensed banks in Hong Kong or the PRC.
2. The Company intends to use the remaining net proceeds in the coming years in accordance with the purpose set out in the Offering Circular, the Company will continue to evaluate the Group's business objectives and will change or modify the plans against the changing market conditions to suit the business growth of the Group. We will issue an appropriate announcement if there is any material change to the above proposed use of proceeds.

CORPORATE GOVERNANCE PRACTICES

The Company recognizes the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of its shareholders as a whole. The Company has adopted the code provisions as set out in the CG Code as contained in Appendix 14 to the Listing Rules, as its own code to govern its corporate governance practices.

Under the code provision A.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Under the current organization structure of the Company, Mr. Mao is the chairman and chief executive officer of the Company. With his extensive experience in the industry, the Board believes that vesting the roles of both chairman and chief executive officer in the same person provides the Company with strong and consistent leadership, allows for effective and efficient planning and implementation of business decisions and strategies, and is beneficial to the business prospects and management of the Group. Although Mr. Mao performs both the roles of chairman and chief executive officer, the division of responsibilities between the chairman and chief executive officer is clearly established. In general, the chairman is responsible for supervising the functions and performance of the Board, while the chief executive officer is responsible for the management of the business of the Group. The two roles are performed by Mr. Mao distinctly. We also consider that the current structure does not impair the balance of power and authority between the Board and the management of the Company given the appropriate delegation of the power of the Board and the effective functions of the independent non-executive Directors. However, it is the long-term objective of the Company to have these two roles performed by separate individuals when suitable candidates are identified.

Save as disclosed above, during the six months ended June 30, 2020, the Company has complied with the CG Code.

The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance.

Supplementary Information

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Group's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company or its securities.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the six months ended June 30, 2020. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of the Group during the six months ended June 30, 2020.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended June 30, 2020, the Company repurchased 3,652,500 Shares on the Stock Exchange for an aggregate consideration of approximately HK\$15.2 million including expenses. The repurchased shares were subsequently cancelled. The repurchase was effected because the Board considered that the trading price of the Shares does not reflect their intrinsic value and this presents a good opportunity for the Company to repurchase the Shares, thereby enhancing the value of Shares and improving return to Shareholders of the Company.

Details of the Shares repurchased are as follows:

Month of repurchase	No. of shares repurchased	Highest price paid per share (HK\$)	Lowest price paid per share (HK\$)	Aggregate Consideration ⁽¹⁾ (HK\$'000)
January 2020	2,673,500	4.290	4.130	11,295.4
April 2020	979,000	4.030	3.940	3,896.5
Total	3,652,500			15,191.9

(1) Aggregate consideration inclusive of expenses.

The Group has also repurchase US\$4,500,000 of the 2025 Convertible Bonds on April 16, 2020 for an aggregate consideration of US\$3,870,000 (equivalent to RMB31,855,000), with a gain on repurchase of 2025 Convertible Bonds of US\$630,000 (equivalent to RMB4,447,000) recognized.

Supplementary Information

Save as disclosed above, neither the Company nor any member of the Group purchased, sold or redeemed any of the Shares during the six months ended June 30, 2020. Please refer to the section headed “Share Incentive Schemes” for information in relation to the issue of Shares pursuant to options exercised under the Pre-IPO Share Incentive Scheme.

REVIEW OF FINANCIAL INFORMATION

Audit Committee

The audit committee of the Company, comprising Ms. Li Xiangrong, Mr. Wang Haiguang, and Mr. Fu Lei, has discussed with the management and reviewed the unaudited interim financial information of the Group for the Reporting Period.

In addition, the Company’s external auditor, Ernst & Young, has performed an independent review of the Group’s interim financial information for the Reporting Period in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. Based on their review, Ernst & Young confirmed that nothing has come to their attention that causes them to believe that the condensed consolidated interim financial information for the Reporting Period is not prepared, in all material respects, in accordance with International Accounting Standard 34 “Interim Financial Reporting”.

CHANGES IN THE BOARD AND THE DIRECTORS’ INFORMATION

There was no change in the Board and the information of Directors since the date of the Company’s 2019 annual report which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

CONTINUING DISCLOSURE OBLIGATION PURSUANT TO THE LISTING RULES

Save as disclosed in this interim report, the Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

Supplementary Information

INTERESTS OF THE DIRECTORS AND CHIEF EXECUTIVE IN SECURITIES

As at June 30, 2020, the interests or short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any associated corporation (within the meaning of Part XV of the SFO), which (a) were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she was taken or deemed to have under such provisions of the SFO); or (b) were required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein; or (c) were required to be notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

Long position in ordinary Shares

Name of Director	Capacity	Number of ordinary shares interested ⁽¹⁾	Approximate percentage ⁺ of the Company's issued share capital
Mr. Mao Chen Cheney ⁽²⁾	Beneficial owner	326,910,365 (L)	19.38%
	Trustee	87,782,186 (L)	5.20%
	Beneficiary of a trust (other than a discretionary interest)	66,425,976 (L)	3.94%
Mr. Hua Fengmao ⁽³⁾	Interest in controlled corporation	123,857,056 (L)	7.34%
	Beneficial owner	2,194,555 (L)	0.13%
	Beneficiary of a trust (other than a discretionary interest)	8,339,308 (L)	0.49%
Ms. Mao Jun ⁽⁴⁾	Beneficiary of a trust (other than a discretionary interest)	311,696,136 (L)	18.48%
Mr. Wu Ying ⁽⁵⁾	Beneficiary of a trust (other than a discretionary interest)	4,358,386 (L)	0.26%
	Interest of spouse	4,164,654 (L)	0.25%
Mr. Ren Delin ⁽⁶⁾	Beneficial owner	11,791,587(L)	0.70%
	Beneficiary of a trust (other than a discretionary interest)	5,266,931(L)	0.31%
	Beneficial owner	9,553,317(L)	0.57%

Notes:

(1) The letter "L" denotes the person's long position in the Shares.

Supplementary Information

- (2) Mr. Mao is the settlor and trustee of the Mao Investment Trust and is interested in the Shares held by him in his capacity as trustee of the Mao Investment Trust. Mr. Mao is also a beneficiary of Min Zhou 2018 Family Trust, CCMFT Trust Scheme and The Chen Mao Charitable Remainder Trust respectively.
- (3) Mr. Hua holds 100.00% equity interest in China Finance Strategies. Therefore, Mr. Hua is deemed to be interested in the Shares directly held by China Finance Strategies. Mr. Hua is also a beneficiary of Vivastar Trust Scheme.
- (4) Each of Mao and Sons, and Zhang and Sons is indirectly wholly-owned by Intertrust (Singapore) Ltd. as the trustee of the Z&M Trust (whose interest is held through Z&M International Holdings Limited). Each of JL and JSW Holding Limited, MENGL Holding Limited, TIANL Holding Limited and VVBI Limited is indirectly wholly-owned by Intertrust (Singapore) Ltd. as the trustee of the VVBI Trust (whose interest is held through VVBI Holdings Limited). Each of the Z&M Trust and the VVBI Trust is a revocable family trust set up by Ms. Mao as settlor and protector. Ms. Mao is also a beneficiary of the relevant family trusts. Therefore, Ms. Mao is deemed to be interested in the Shares directly held by each of Mao and Sons, Zhang and Sons, JL and JSW Holding Limited, MENGL Holding Limited, TIANL Holding Limited and VVBI Limited.
- (5) Mr. Wu Ying is a beneficiary of Vivastar Trust Scheme and he is the spouse of Ms. Zhao Huixin. Under the SFO, Mr. Wu Ying is deemed to be interested in the same number of Shares in which Ms. Zhao Huixin is interested in.
- (6) Mr. Ren Delin is a beneficiary of Vivastar Trust Scheme.
- + The percentage represents the number of ordinary shares/underlying shares interested divided by the number of the Company's issued shares as at June 30, 2020.

(ii) Interests in associated corporations of the Company

Name of Director	Name of associated corporation	Capacity/nature of interest	Class of shares in which interested	Number of shares	Percentage of shareholding of the class
Mr. Mao Chen Cheney	Anji Pharmaceuticals Inc. ⁽²⁾	Interest in controlled corporation	Ordinary	12,398,500 (L)	24.80%
	Clues Therapeutics Inc. ⁽²⁾	Interest in controlled corporation	Ordinary	20,257,515 (L)	17.73%
Mr. Hua Fengmao	Anji Pharmaceuticals Inc. ⁽³⁾	Interest in controlled corporation	Series seed preferred shares	1,500,000 (L)	7.06%
	Anji Pharmaceuticals Inc. ⁽³⁾	Interest in controlled corporation	Ordinary	4,093,500 (L)	8.19%
	Clues Therapeutics Inc. ⁽³⁾	Interest in controlled corporation	Ordinary	6,400,000 (L)	5.60%
Ms. Mao Jun	Anji Pharmaceuticals Inc. ⁽⁴⁾	Interest in controlled corporation	Series A-2 preferred shares	17,437,500 (L)	41.67%

Supplementary Information

Name of Director	Name of associated corporation	Capacity/nature of interest	Class of shares in which interested	Number of shares	Percentage of shareholding of the class
	Anji Pharmaceuticals Inc. ⁽⁴⁾	Beneficiary of a trust (other than a discretionary interest)	Series seed preferred shares	5,000,000 (L)	23.53%
	Anji Pharmaceuticals Inc. ⁽⁴⁾	Beneficiary of a trust (other than a discretionary interest)	Ordinary	10,117,000 (L)	20.23%
	Clues Therapeutics Inc. ⁽⁵⁾	Beneficiary of a trust (other than a discretionary interest)	Ordinary	12,257,515 (L)	10.73%
	Flash Therapeutics, LLC	Interest in controlled corporation	Class C preferred shares	210,732	100%
	Proviva Therapeutics, Inc.	Interest in controlled corporation	Series seed preferred shares	175,000	1.00%

Notes:

- (1) The letter “L” denotes the person’s long position in the shares.
- (2) Mr. Mao holds 100.0% equity interest in Chencheney Ltd. Therefore, Mr. Mao is deemed to be interested in the shares of Anji Pharmaceuticals and Clues Therapeutics directly held by Chencheney Ltd. Chencheney Ltd, the corporation controlled by director has entered into Convertible Note Purchase Agreement with Clues Therapeutics Inc. to subscribe for the 8% Convertible Promissory Note in the aggregate principal amount of US\$447,039.092. The conversion price under which the Convertible Note is convertible into shares is subject to adjustments in accordance with the mechanism of the Convertible Note and reflects the calculation made on the day hereof.
- (3) Mr. Hua holds 100.0% equity interest in H&D Biotech Investment Limited. Therefore, Mr. Hua is deemed to be interested in the shares of Anji Pharmaceuticals and Clues Therapeutics directly held by H&D Biotech Investment Limited.
- (4) Each of Mao and Sons, Zhang and Sons is indirectly wholly-owned by Intertrust (Singapore) Ltd. as the trustee of the Z&M Trust. Ms. Mao is the settlor, protector and a beneficiary of the Z&M Trust. Therefore, Ms. Mao is deemed to be interested in the shares of Anji Pharmaceuticals directly held by Zhang and Sons and Mao and Sons.
- (5) Zhang and Sons is indirectly wholly-owned by Intertrust (Singapore) Ltd. as the trustee of the Z&M Trust (whose interest is held through Z&M International Holdings Limited). Ms. Mao is the settlor, protector and a beneficiary of the Z&M Trust. Therefore, Ms. Mao is deemed to be interested in the shares of Clues Therapeutics directly held by Zhang and Sons.

Supplementary Information

Save as disclosed in this interim report and to the best knowledge of the Directors, as at June 30, 2020, none of the Directors or the chief executive of the Company has any interests and/or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein or which were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' INTERESTS IN SECURITIES

So far as is known to any Director or chief executive of the Company, as at June 30, 2020, the following corporations/persons (other than the Directors or the chief executive of the Company) had interests of 5% or more in the issued shares of the Company according to the register of interests required to be kept by the Company under section 336 of the SFO:

Name	Capacity	Number of ordinary shares interested⁽¹⁾	Approximate percentage⁺ of the Company's issued share capital
Zhang and Sons Limited ⁽²⁾	Beneficial owner	159,433,021 (L)	9.45%
Fenghe Harvest Ltd ⁽³⁾	Beneficial owner	154,821,323 (L)	9.18%
China Finance Strategies Investment DB Limited ⁽⁴⁾	Beneficial owner	123,857,056 (L)	7.34%
Mr. WU John Jiong ⁽³⁾	Interest in controlled corporation	232,792,092 (L)	13.80%
Z&M International Holdings Limited ⁽²⁾	Interest in controlled corporation	210,371,206 (L)	12.47%
Intertrust (Singapore) Ltd. ⁽²⁾	Trustee	223,913,950 (L)	13.27%

Supplementary Information

Notes:

- (1) The letter “L” denotes the person’s long position in the Shares.
 - (2) Each of Mao and Sons, and Zhang and Sons is indirectly wholly-owned by Intertrust (Singapore) Ltd. as the trustee of the Z&M Trust (whose interest is held through Z&M International Holdings Limited). Each of JL and JSW Holding Limited, MENGL Holding Limited, TIANL Holding Limited and VVBI Limited is indirectly wholly-owned by Intertrust (Singapore) Ltd. as the trustee of the VVBI Trust (whose interest is held through VVBI Holdings Limited). Each of the Z&M Trust and the VVBI Trust is a revocable family trust set up by Ms. Mao as settlor and protector. Ms. Mao is also a beneficiary of the relevant family trusts. Therefore, Ms. Mao is deemed to be interested in the Shares directly held by each of Mao and Sons, Zhang and Sons, JL and JSW Holding Limited, MENGL Holding Limited, TIANL Holding Limited and VVBI Limited.
 - (3) Mr. John Wu Jiong holds 100.00% equity interest in each of Fenghe Harvest and Wu and Sons. In addition, Mr. John Wu Jiong holds 45.00% equity interest in FengHe Canary. Therefore, Mr. John Wu Jiong is deemed to be interested in the Shares directly held by Fenghe Harvest, Wu and Sons and FengHe Canary.
 - (4) Mr. Hua holds 100.00% equity interest in China Finance Strategies. Therefore, Mr. Hua is deemed to be interested in the Shares directly held by China Finance Strategies.
- + The percentage represents the number of ordinary Shares interested divided by the number of the issued Shares as at June 30, 2020.

Save as disclosed above and to the best knowledge of the Directors, as at June 30, 2020, no person (other than the Directors or chief executives of the Company) had registered an interest or a short position in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company under section 336 of the SFO.

SHARE INCENTIVE SCHEMES

1. Pre-IPO Share Incentive Schemes

(a) Purpose and Principal Terms

The purposes of the 2009 Stock Incentive Plan, the 2018 Stock Incentive Plan and the Pre-IPO Stock Incentive Plan are to enable the Group to grant options or awards to eligible persons (as determined by the Board or any committee designated by the Board to administer the scheme the “**Administrator**”) including employees, directors and consultants of the Company or any related entity for purpose of attracting and retaining the best available personnel. The principal terms of the 2009 Stock Incentive Plan, the 2018 Stock Incentive Plan and the Pre-IPO Stock Incentive Plan are substantially the same, except for the maximum number of Shares which may be issued under each plan. The principal terms of the Pre-IPO Share Incentive Schemes are as follows:

- (i) Subject to any alterations set out under the Pre-IPO Share Incentive Schemes in the event of any share split, reverse share split, share dividend, combination or reclassification of Shares, increase or decrease of issued Shares effected without receipt of consideration by the Company and certain corporate transactions, the maximum number of Shares in respect of which options or awards may be granted under the 2009 Stock Incentive Plan, the 2018 Stock Incentive Plan and the Pre-IPO Stock Incentive Plan shall be 270,937,302 Shares (as adjusted for the increase in the number of issued shares resulting from a share split in January 2010 and adjusted after the capitalization issue), 57,892,351 Shares (adjusted after the capitalization issue) and 2,194,555 Shares (adjusted after the capitalization issue), respectively, in an aggregate representing approximately 22.07% of the issued share capital of the Company immediately before completion of the Global Offering but after completion of the capitalization issue;
- (ii) No option or award under the Pre-IPO Share Incentive Schemes will be granted after Listing;
- (iii) No consideration were paid by the grantees for the options and awards granted under the Pre-IPO Share Incentive Schemes;

Supplementary Information

- (iv) Subject to the terms of the Pre-IPO Share Incentive Schemes and the terms set out in the notice of stock option award and the stock option award agreement entered into at the time of grant (the “**Stock Option Award Agreements**”), (i) if the option (“**Qualified Incentive Share Option**”) is intended to qualify as an incentive stock option within the meaning of Section 422 of the Internal Revenue Code of 1986 (as amended) (the “**Code**”), it may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the grantee, only by the grantee; (ii) if the option is not intended to qualify as a Qualified Incentive Share Option (“**Non-qualified Incentive Share Option**”), it shall be transferable (a) by will and by the laws of descent and distribution and (b) during the lifetime of the grantee, to the extent and in the manner authorized by the Administrator. Notwithstanding the foregoing, the grantee may designate one or more beneficiaries of the grantee’s award in the event of the grantee’s death;
- (v) Subject to the terms of the Pre-IPO Share Incentive Schemes and the terms set out in the Stock Option Award Agreements, the options and awards under the Pre-IPO Share Incentive Schemes shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at fair market value) for all of awards outstanding or to the extent not assumed or replaced (as applicable) in the event of change of control or certain corporate transactions as defined under the Pre-IPO Share Incentive Schemes;
- (vi) Subject to the terms of the Pre-IPO Share Incentive Schemes and the terms set out in the Stock Option Award Agreements, the options and awards under the Pre-IPO Share Incentive Schemes, (i) in the case of a Qualified Incentive Share Option, (a) if granted to an employee who, at the time of the grant of such Qualified Incentive Share Option owns shares representing more than 10% of the voting power of all classes of shares of the Company or any parent or subsidiary of the Company, the per Share exercise price shall be not less than 110% of the fair market value per Share on the date of grant; (b) if granted to any employee other than an employee described in the preceding paragraph, the per Share exercise price shall be not less than 100% of the fair market value per Share on the date of grant; (ii) in the case of a Non-qualified Incentive Share Option, the per Share exercise price shall be not less than 85% of the fair market value per Share on the date of grant unless otherwise determined by the Administrator; (iii) In the case of other awards, such price as is determined by the Administrator;

Supplementary Information

- (vii) Each grantee to whom an option or award has been granted shall be entitled to the Shares they are awarded in accordance with the terms (including any restrictions and vesting requirement that may be imposed) of the Pre-IPO Share Incentive Schemes and the Stock Option Award Agreements, provided, however, that the term of a Qualified Incentive Share Option shall be no more than ten years from the date of grant thereof;
- (viii) An award may be exercised following the termination of a grantee's continuous service only to the extent provided in the Stock Option Award Agreements;
- (ix) The Board may at any time amend, suspend or terminate the Pre-IPO Share Incentive Schemes; provided, however, that no such amendment shall be made without the approval of the Company's shareholders to the extent such approval is required by applicable laws. No suspension or termination of the Pre-IPO Share Incentive Schemes shall adversely affect any rights under awards already granted to a grantee.

The Pre-IPO Share Incentive Schemes do not involve the grant of the option to subscribe for any new Shares and therefore is not required to be subject to the provisions in Chapter 17 of the Listing Rules. It does not cause any effect to the total number of Shares outstanding and will not result in any dilution effect to the Shares.

Each of Mr. Mao Chen Cheney, Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin, as the executive Director and as the scheme participant holds directorship in the Company.

Name and category of participant	Date of grant	Number of options				As of June 30, 2020	Vesting period
		As of January 1, 2020	Exercised during the Reporting Period	Canceled during the Reporting Period	Lapsed during the Reporting Period		
Directors and their associates							
Mr. Mao	January 2, 2018	2,194,555	2,194,555	-	-	0	(Note 1)
Mr. Wu Ying	January 2, 2018	4,358,386	4,358,386	-	-	0	(Note 1)
Mr. Hua	January 2, 2018	8,339,308	2,194,555	-	-	6,144,753	(Note 1)
	June 21, 2018	2,194,555	2,194,555	-	-	0	(Note 3)
Mr. Ren Delin	January 2, 2018	5,266,931	-	-	-	5,266,931	(Note 1)
Mrs. Zhao Huixin ⁽⁴⁾	January 2, 2018	2,852,922	2,852,922	-	-	0	(Note 1)
Subtotal		25,206,657	13,794,973	-	-	11,411,684	

Supplementary Information

Name and category of participant	Date of grant	Number of options				As of June 30, 2020	Vesting period
		As of January 1, 2020	Exercised during the Reporting Period	Canceled during the Reporting Period	Lapsed during the Reporting Period		
Other employees	January 2, 2018	28,976,908	16,823,455	-	-	12,153,453	(Note 1)
	January 2, 2018	4,937,748	651,781	-	-	4,285,967	(Note 2)
Subtotal		33,914,656	17,475,236	-	-	16,439,420	
Total		59,121,313	31,270,209	-	-	27,851,104	

Notes:

- (1) 100% of the options shall be fully vested and exercisable on the second anniversary of the date of grant.
- (2) 40% of the options shall vest on the second anniversary of the date of grant, 20% of the options shall vest on the third anniversary of the date of grant, 20% of the options shall vest on the fourth anniversary of the date of grant, and the remaining 20% of the options shall vest on the fifth anniversary of the date of grant.
- (3) 100% of the options shall vest upon completion of the Global Offering.
- (4) Mrs. Zhao Huixin is an employee of the Group and the spouse of Mr. Wu Ying.

2. Post-IPO Share Option Scheme

The Post-IPO Share Option Scheme was adopted pursuant to the resolutions of the Shareholders on April 14, 2019, which falls within the ambit of, and is subject to, the regulations under Chapter 17 of the Listing Rules.

The purpose of the Post-IPO Share Option Scheme is to provide Eligible Participants (as defined below) with the opportunity to acquire proprietary interests in the Company and to encourage Eligible Participants to work towards enhancing the value of the Company and its Shares for the benefit of the Company and its Shareholders as a whole.

The Board of Directors may subject to and in accordance with the provisions of the Post-IPO Share Option Scheme and the Listing Rules, at its discretion grant options to any directors (including executive directors, non-executive directors and independent non-executive directors) and employees of any member of the Group and any advisors, consultants, distributors, contractors, customers, suppliers, agents, business partners, joint venture business partners, services providers of any member of the Group who, in the absolute discretion of the Board, has contributed or will contribute to the Group (collectively, the “**Eligible Participants**”).

The Post-IPO Share Option Scheme shall be valid and effective for a period of ten years commencing from the Listing Date (the “**Scheme Period**”), after which time no further option shall be offered or granted but the provisions of the Post-IPO Share Option Scheme shall remain in full force and effect in all other respects to the extent necessary to give effect to the exercise of any options granted prior thereto or otherwise as may be required in accordance with the provisions of the Post-IPO Share Option Scheme.

Each grant of options to any director, chief executive or substantial shareholder of the Company or any of their respective associates shall be subject to prior approval of the independent non-executive directors of the Company (excluding any independent non-executive director who is a proposed recipient of the grant of options). Where any grant of options to a substantial shareholder or an independent non-executive director of the Company (or any of their respective associates) would result in the number of Shares issued and to be issued upon exercise of all options already granted and to be granted (including options exercised, cancelled and outstanding) to such person in the 12 months period up to and including the date of such grant:

- i. representing in aggregate over 0.1 per cent, or such other percentage as may from time to time be specified by the Stock Exchange, of the Shares in issue; and
- ii. having an aggregate value, based on the closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange on the Date of Grant, in excess of HK\$5 million (or such other higher amount as may from time to time be specified by the Stock Exchange).

Supplementary Information

such further grant of options shall be subject to prior approval by the Shareholders (voting by way of poll) in general meeting. The Company shall send a circular to its Shareholders no later than the date on which the Company gives notice of the general meeting to approve such grant. The relevant Eligible Participant, his associates and all core connected persons of the Company shall abstain from voting at such general meeting, except that such person may vote against the relevant resolution at the general meeting provided that his/her intention to do so has been stated in the circular to be sent to the Shareholders in connection therewith. The circular to be issued by the Company shall contain (i) the details of the number and terms (including the Subscription Price) of the options to be granted to each Eligible Participant which must be fixed before the Shareholders' meeting and the date of board meeting for proposing such further grant is to be taken as the Date of Grant for the purpose of calculating the exercise price; and (ii) a recommendation from the independent non-executive directors of the Company (excluding the independent non-executive director who is the relevant Eligible Participant) to the independent Shareholders stating their recommendation as to whether to vote for or against the resolution relating to the grant of the options; and (iii) other information required under relevant Listing Rules.

The price per Share at which a Grantee may subscribe for Shares upon exercise of an option (the "**Subscription Price**") shall be a price determined by the Board in its sole discretion and notified to the Grantee and shall be no less than the highest of:

- i. the closing price of the Shares as stated in the Stock Exchange's daily quotations sheets on the date on which the Board resolves to make the offer of the option (the "**Date of Grant**");
- ii. the average closing price of the Shares as stated in the Stock Exchange's daily quotation sheets for the five business days immediately preceding the Date of Grant (provided that in the event that any option is proposed to be granted within a period of less than five business days after the trading of the Shares first commences on the Stock Exchange, the final issue price of the Shares for the Global Offering shall be used as the closing price for any business day falling within the period before listing of the Shares on the Stock Exchange); and
- iii. the nominal value of a Share on the Date of Grant.

The Shares which may be issued upon exercise of all options granted under the Post-IPO Share Option Scheme and any other share option schemes of the Company shall not in aggregate exceed 10% of the total number of Shares in issue as at the date dealings in Shares on the Stock Exchange commence (excluding any Shares which may be allotted and issued pursuant to the exercise of the Over-allotment Option or the exercise of options which were granted under the Pre-IPO Share Incentive Schemes or may be granted under the Post-IPO Share Option Scheme) (the "**Scheme Limit**") which is expected to be 150,000,000 Shares. For the purposes of calculating the Scheme Limit, options which have lapsed in accordance with the terms of the relevant Scheme shall not be counted.

Supplementary Information

Subject to the terms of the Post-IPO Share Option Scheme, the Company may refresh the Scheme Limit at any time subject to prior approval of the Shareholders in general meeting and/or such other requirements prescribed under the Listing Rules from time to time. However, the renewed scheme limit as refreshed shall not exceed 10% of the Shares in issue as at the date of the aforesaid approval by the Shareholders in general meeting. Options previously granted under the Post-IPO Share Option Scheme, whether outstanding, canceled, lapsed in accordance with its applicable terms or already exercised, will not be counted for the purpose of calculating the limit as renewed. A circular in accordance with the requirements of the Listing Rules shall be sent to the Shareholders in connection with the meeting at which their approval will be sought.

Notwithstanding anything to the contrary in the Post-IPO Share Option Scheme, the overall limit on the number of Shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the Post-IPO Share Option Scheme and any other schemes of the Company must not in aggregate exceed 30% of the Shares in issue from time to time. No options may be granted if such grant will result in this 30% limit being exceeded.

Unless approved by the Shareholders in general meeting, the Board shall not grant options to any Eligible Participant if the acceptance of those options would result in the total number of shares issued and to be issued to that Grantee on exercise of his option during any 12 months period up to the offer date exceeding 1% of the total Shares then in issue.

Where any further grant of options to a Eligible Participant, if exercised in full, would result in the total number of Shares already issued or to be issued upon exercise of all options granted and to be granted to such Eligible Participant (including exercised, canceled and outstanding options) in any 12-month period up to and including the date of such further grant exceeding 1% of the total number of Shares in issue, such further grant must be separately approved by the Shareholders in general meeting with such Grantee and his close associates (or his associates of the Eligible Participant is a connected person) abstaining from voting. The Company must send a circular to the Shareholders and the circular must disclose the identity of the Grantee, the number and terms of the options to be granted and options previously granted to such Grantee and all other information required under the Listing Rules. The number and terms (including the Subscription Price) of the options to be granted to such Eligible Participant must be fixed before the Shareholders' approval. The date of the meeting of the Board for proposing such further grant of option should be taken as the date of grant for the purpose of calculating the Subscription Price.

Supplementary Information

On May 21, 2020, the Company granted share options to certain eligible participants to subscribe for a total of 17,110,000 ordinary shares in the share capital of the Company, at the price of HK\$7.61 per Share. The closing price of the Shares on the date of grant of such options was HK\$7.61 per Share. None of the grantees of the share options is a Director, chief executive or substantial shareholder of the Company or an associate of any of them.

Details of the options granted under the Post-IPO Share Option Scheme and those remained outstanding as at June 30, 2020 are as follows:

Category of participant	Date of Grant	Number of options					As of June 30, 2020	Vesting period
		As of January 1, 2020	Granted during the Reporting Period	Exercised during the Report Period	Cancelled during the Report Period	Lapsed during the Report Period		
Other Employees	May 21, 2020	-	16,990,000 ⁽¹⁾	-	-	60,000	16,930,000	(Note 2)
Total		-	16,990,000			60,000	16,930,000	

Note:

- (1) On May 21, 2020, the Board announced the granting of share options to employees of the Group pursuant to the Post-IPO Share Option Scheme to subscribe for an aggregate of 17,110,000 Shares, of which options to subscribe for 16,990,000 Shares were taken up by employees of the Group.
- (2) Subject to vesting conditions including performance target of both the Group and the grantee, (i) 30% of Share Options granted to each grantee shall be vested on May 21, 2021, (ii) an additional 30% shall be vested on May 21, 2022 and (iii) the remaining 40% shall be vested on May 21, 2023.

The Group's performance target for the three tranches of share options referred to in the preceding paragraph is that the Group's revenue for the 2020, 2021 and 2022 financial year as recorded in the Company's audited consolidated financial statements shall increase by no less than 30%, 60% and 90% as compared to the Group's revenue for the 2019 financial year, respectively.

Details of the impact of the options granted under the Post-IPO Share Option Scheme on the consolidated financial statements since the date of grant of such options and the subsequent financial periods are set out under Note 17 to the consolidated financial statements in this interim report.

A summary of the terms of the Pre-IPO Share Incentive Schemes and Post-IPO Share Option Scheme has been set out in the section headed "D. Share Incentive Schemes" in Appendix IV of the Prospectus.

3. Restricted Share Unit Scheme

On June 5, 2020, the Board considered and approved of the Restricted Share Unit Scheme, the principal terms of the Restricted Share Unit Scheme is set out in the Company's announcement on the same date.

The Company has appointed Tricor Trust (Hong Kong) Limited as the trustee to assist with the the administration and vesting of the awards pursuant to the Restricted Share Unit Scheme. The Shares forming the share pool under the Restricted Share Unit Scheme shall be purchased from the secondary market and the aggregate amount of Shares to be purchased shall not exceed 20,000,000 Shares and will be funded out of the Company's internal resources. No Shares will be allotted and issued by the Company pursuant to Restricted Share Unit Scheme. As the Restricted Share Unit Scheme does not involve the grant of options to subscribe for any new Shares of the Company, it is not required to be subject to the provisions under Chapter 17 of the Listing Rules.

From the date of approval of the Restricted Share Unit Scheme to the end of the Report Period, no restricted share unit has been granted or agreed to be granted under the Restricted Share Unit Scheme since its adoption.

SUBSEQUENT EVENT

1. On July 1, 2020, the Company announced that Viva Biotech Shanghai had successfully entered into a bid for the land use right of the property by way of internet auction through taobao.com (淘寶網) published by the Shanghai Pudong District People's Court (上海市浦東新區人民法院) at a bidding price of RMB392,370,000 and obtained the internet auction confirmation on the same day. The Company expects that the acquisition of the property will provide operating space to meet the Group's business growth and development in the coming years.
2. On July 10, 2020, an aggregate of 130,000,000 placing shares were placed at the placing price of HK\$8.15 per placing share, representing 7.07% of the issued share capital of the Company as enlarged by the allotment and issued of the placing shares immediately upon completion of the placing. The net proceeds from the placing, after deduction of the placing commission and other related expenses, amounted to approximately HK\$1,050,730,000 (equivalent to RMB948,263,000).
3. On August 8, 2020, Viva Biotech Shanghai entered into the share purchase agreement pursuant to which Viva Biotech Shanghai agreed to acquire 80% of the equity interest in Zhejiang Langhua Pharmaceutical Co., Ltd., at the consideration of RMB2,560,000,000, which will be satisfied by cash.

Independent Review Report



Ernst & Young
22/F, CITIC Tower
1 Tim Mei Avenue
Central, Hong Kong

安永會計師事務所
香港中環添美道1號
中信大廈22樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

TO THE BOARD OF DIRECTORS OF VIVA BIOTECH HOLDINGS
(Incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 37 to 75, which comprises the condensed consolidated statement of financial position of Viva Biotech Holdings (the “**Company**”) and its subsidiaries (the “**Group**”) as at June 30, 2020 and the related condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* (“**IAS 34**”) issued by the International Accounting Standards Board (“**IASB**”). The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the HKICPA. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young
Certified Public Accountants
Hong Kong

August 31, 2020

Interim Condensed Consolidated Statement of Profit or Loss

For the six months ended June 30, 2020

	<i>Notes</i>	2020 <i>RMB'000</i> (Unaudited)	2019 <i>RMB'000</i> (Unaudited)
REVENUE	3	197,557	142,341
Cost of services		(97,439)	(70,450)
Gross profit		100,118	71,891
Other income and gains	4	27,190	34,208
Selling and distribution expenses		(1,951)	(1,837)
Administrative expenses		(37,048)	(22,359)
Research and development expenses		(22,324)	(15,616)
Listing expenses		–	(17,909)
Fair value gain on financial assets at fair value through profit or loss (“FVTPL”)	15	66,658	48,168
Impairment losses on financial assets, net		(434)	(1,324)
Other expenses		(161)	(13)
Finance costs	5	(38,594)	(872)
Share of losses of:			
A joint venture		(321)	(909)
An associate		–	(34)
PROFIT BEFORE FAIR VALUE LOSS ON FINANCIAL LIABILITIES AT FVTPL AND TAX		93,133	93,394
Fair value loss on financial liabilities at FVTPL	18	(615,526)	(34,238)
(LOSS)/PROFIT BEFORE TAX	6	(522,393)	59,156
Income tax expense	7	(7,879)	(12,660)
(LOSS)/PROFIT FOR THE PERIOD		(530,272)	46,496
		RMB	RMB
(LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	8		
Basic		(0.38)	0.04
Diluted		(0.38)	0.03

Interim Condensed Consolidated Statement of Comprehensive Income

For the six months ended June 30, 2020

	2020 <i>RMB'000</i> (Unaudited)	2019 <i>RMB'000</i> (Unaudited)
(LOSS)/PROFIT FOR THE PERIOD	(530,272)	46,496
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	7,150	–
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	7,150	–
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD	(523,122)	46,496
Attributable to:		
Owners of the parent	(523,122)	46,496

Interim Condensed Consolidated Statement of Financial Position

June 30, 2020

	<i>Notes</i>	June 30, 2020 <i>RMB'000</i> (Unaudited)	December 31, 2019 <i>RMB'000</i> (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	10	163,904	106,348
Right-of-use assets	10	151,053	50,638
Interests in a joint venture		3,907	4,228
Financial assets at FVTPL	15	760,123	622,854
Contract assets		10,728	5,405
Rental deposits and prepayments		27,002	11,097
Deferred tax assets		7,185	3,789
Total non-current assets		1,123,902	804,359
CURRENT ASSETS			
Inventories		9,669	8,530
Trade receivables	11	69,642	57,505
Contract costs		6,341	5,612
Prepayments, other receivables and other assets	12	44,005	83,151
Financial assets at FVTPL	15	95,652	29,629
Restricted bank balances		71,614	5,908
Cash and cash equivalents		1,521,285	904,091
Time deposits with original maturity of over three months		355,933	–
Total current assets		2,174,141	1,094,426
CURRENT LIABILITIES			
Trade payables	13	6,281	7,552
Other payables and accruals	14	89,085	28,394
Derivative financial instruments		503	–
Interest-bearing bank borrowings		15,902	525
Contract liabilities		1,816	635
Lease liabilities		10,924	24,458
Income tax payable		9,651	11,399
Total current liabilities		134,162	72,963
NET CURRENT ASSETS		2,039,979	1,021,463
TOTAL ASSETS LESS CURRENT LIABILITIES		3,163,881	1,825,822

Interim Condensed Consolidated Statement of Financial Position

June 30, 2020

	<i>Notes</i>	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
NON-CURRENT LIABILITIES			
Interest-bearing bank borrowings		1,067	1,340
Convertible bonds – debt component	18	537,634	–
Convertible bonds – embedded derivative instruments	18	687,043	–
Deferred income		20,294	15,844
Lease liabilities		9,185	23,084
Deferred tax liabilities		9,910	8,160
Total non-current liabilities		1,265,133	48,428
Net Assets		1,898,748	1,777,394
EQUITY			
Equity attributable to owners of the parent			
Share capital	16	283	261
Other reserves		1,898,465	1,777,133
Total Equity		1,898,748	1,777,394

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended June 30, 2020

	Share capital <i>RMB'000</i>	Share premium <i>RMB'000</i>	Exchange fluctuation reserve <i>RMB'000</i>	Share option reserve <i>RMB'000</i>	Statutory reserves <i>RMB'000</i>	Retained earnings <i>RMB'000</i>	Total <i>RMB'000</i>
At January 1, 2020 (audited)	261	1,298,673	231	28,815	25,263	424,151	1,777,394
Loss for the period	-	-	-	-	-	(530,272)	(530,272)
Other comprehensive income for the period:							
Exchange differences on translation of foreign operations	-	-	7,150	-	-	-	7,150
Total comprehensive income for the period	-	-	7,150	-	-	(530,272)	(523,122)
Final 2019 dividend declared	-	(23,037)	-	-	-	-	(23,037)
Equity-settled share option arrangements	-	-	-	2,360	-	-	2,360
Exercise of share options	6	32,104	-	-	-	-	32,110
Conversion of convertible bonds	17	646,607	-	-	-	-	646,624
Repurchase of ordinary shares	(1)	(13,580)	-	-	-	-	(13,581)
At June 30, 2020 (unaudited)	283	1,940,767	7,381	31,175	25,263	(106,121)	1,898,748
At January 1, 2019 (audited)	164	47,251	-	20,485	16,207	167,335	251,442
Profit and total comprehensive income for the period	-	-	-	-	-	46,496	46,496
Equity-settled share option arrangements	-	-	-	4,323	-	-	4,323
Capitalization Issue	17	(17)	-	-	-	-	-
Dividend declared	-	(120,747)	-	-	-	-	(120,747)
Automatic conversion of Series B Preferred Shares upon Global Offering	11	246,888	-	-	-	-	246,899
Shares issued upon Global Offering and over-allotment	60	1,339,920	-	-	-	-	1,339,980
Share issue expenses	-	(80,687)	-	-	-	-	(80,687)
Exercise of share options	15	5,648	-	-	-	-	5,663
At June 30, 2019 (unaudited)	267	1,438,256	-	24,808	16,207	213,831	1,693,369

Interim Condensed Consolidated Statement of Cash Flows

For the six months ended June 30, 2020

	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES		
(Loss)/profit before tax	(522,393)	59,156
Adjustments for:		
Finance costs	38,594	872
Share of losses of a joint venture and an associate	321	943
Interest income	(7,851)	(6,995)
Loss on disposal of items of property, plant and equipment	155	13
Fair value gains, net:		
Derivative financial instruments	(1,421)	–
Financial assets at FVTPL	(66,658)	(48,168)
Fair value loss on financial liabilities at FVTPL	615,526	34,238
Foreign exchange gain	(7,462)	(1,032)
Income from government grants and subsidies related to assets	(510)	(1,194)
Revenue from service-for-equity (“SFE”)	(28,756)	(24,340)
Equity-settled share option expense	2,360	4,323
Gain on deemed disposal of interests in associates	–	(9,892)
Gain on repurchase of convertible bonds	(4,447)	–
Transaction cost of convertible bonds	5,068	–
Depreciation of property, plant and equipment	12,399	6,492
Depreciation of right-of-use assets	9,145	6,759
Impairment losses under expected credit model, net of reversal	434	1,324
Gain on disposal of right-of-use assets	(1,145)	–
	43,359	22,499
Increase in inventories	(1,139)	(299)
Increase in contract costs	(636)	(3,516)
(Increase)/decrease in trade receivables	(8,587)	3,859
(Increase)/decrease in other receivables	(167)	2,544
Decrease in trade payables	(1,271)	(843)
Decrease in other payables	(3,833)	(723)
Decrease in deferred revenue	(240)	–
Increase in contract liabilities	1,181	620
Cash generated from operations	28,667	24,141
Income tax paid	(7,731)	(11,566)
Net cash flows from operating activities	20,936	12,575

Interim Condensed Consolidated Statement of Cash Flows

For the six months ended June 30, 2020

	2020 <i>RMB'000</i> (Unaudited)	2019 <i>RMB'000</i> (Unaudited)
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	5,790	6,919
Purchases of items of property, plant and equipment	(49,114)	(15,635)
Proceeds from disposal of items of property, plant and equipment	32	8
Increase in rental deposit	(4,722)	(3,131)
Purchases of time deposit over three months	(353,975)	–
Receipt of government grants and subsidies related to assets	5,200	2,500
Placement of restricted bank deposits	(65,624)	(2,506)
Withdraw in restricted bank deposits	–	4,652
Capital injection of investment in joint ventures	–	(3,500)
Capital injection of investment in associates	–	(3)
Payments for acquisition of a subsidiary	(55,805)	–
Prepayments for potential acquisition of non-current assets	(30,000)	–
Purchase of financial assets at FVTPL	(2,710,867)	(52,981)
Proceeds from disposal of financial assets at FVTPL	2,605,867	–
Receipt of investment income from derivative financial instruments	1,924	–
Net cash flows from investing activities	(651,294)	(63,677)
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of bank borrowings	(259)	(245)
Interest paid	(218)	(61)
Issue costs paid	–	(69,706)
Proceeds from bank borrowings	15,363	–
Proceeds from third party	–	10,631
Repayment of third party	–	(10,631)
Principal portion of lease payments	(21,672)	(3,150)
Proceeds from issue of ordinary shares	–	1,339,980
Proceeds from exercise share option	32,110	5,663
Payment for repurchase of shares	(13,581)	–
Dividend paid	–	(128,686)
Proceeds from the issue of convertible bonds	1,261,148	–
Transaction cost of convertible bonds	(5,156)	–
Payment for repurchase of convertible bonds	(27,398)	–
Net cash flows from financing activities	1,240,337	1,143,795

Interim Condensed Consolidated Statement of Cash Flows

For the six months ended June 30, 2020

	2020 RMB'000 (Unaudited)	2019 <i>RMB'000</i> (Unaudited)
NET INCREASE/ (DECREASE) IN CASH AND CASH EQUIVALENTS		
Cash and cash equivalents at beginning of period	904,091	155,554
Effect of foreign exchange rate changes, net	7,215	1,032
CASH AND CASH EQUIVALENTS AT END OF PERIOD	1,521,285	1,249,279

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

1. CORPORATE INFORMATION AND BASIS OF PREPARATION AND PRESENTATION OF THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.1 Corporate information

Viva Biotech Holdings (the “**Company**”) was incorporated in the Cayman Islands as an exempted company with limited liability on August 27, 2008, and its shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) since May 9, 2019 (the “**Listing Date**”). The address of the registered office and the principal place of business of the Company is PO Box 309, Uglan House, Grand Cayman, KYI-1104, Cayman Islands and Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong respectively.

The Company is an investment holding company. The Company and its subsidiaries (collectively referred to as the “**Group**”) is principally engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development.

1.2 Basis of preparation

The interim condensed consolidated financial information for the six months ended June 30, 2020 has been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2019.

The functional currency of the Company is Renminbi (“**RMB**”), which is the same as the presentation currency of the condensed consolidated financial statements.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

2. CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2019, except for the adoption of the following revised International Financial Reporting Standards (“IFRSs”) for the first time for the current period's financial information.

Amendments to IFRS 3	<i>Definition of a Business</i>
Amendments to IFRS 9, IAS 39 and IFRS 7	<i>Interest Rate Benchmark Reform</i>
Amendments to IFRS 16	<i>Covid-19-Related Rent Concessions (early adopted)</i>
Amendments to IFRS1 and IAS 8	<i>Definition of Material</i>

The nature and impact of the revised IFRSs are described below:

- (a) Amendments to IFRS 3 clarify and provide additional guidance on the definition of a business. The amendments clarify that for an integrated set of activities and assets to be considered a business, it must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output. A business can exist without including all of the inputs and processes needed to create outputs. The amendments remove the assessment of whether market participants are capable of acquiring the business and continue to produce outputs. Instead, the focus is on whether acquired inputs and acquired substantive processes together significantly contribute to the ability to create outputs. The amendments have also narrowed the definition of outputs to focus on goods or services provided to customers, investment income or other income from ordinary activities. Furthermore, the amendments provide guidance to assess whether an acquired process is substantive and introduce an optional fair value concentration test to permit a simplified assessment of whether an acquired set of activities and assets is not a business. The Group has applied the amendments prospectively to transactions or other events that occurred on or after January 1, 2020. Upon the initial application, the 100% equity acquisition of the target company which was completed on March 9, 2020 was identified as asset acquisition.

2. CHANGES IN ACCOUNTING POLICIES (continued)

- (b) Amendments to IFRS 9, IAS 39 and IFRS 7 address the effects of interbank offered rate reform on financial reporting. The amendments provide temporary reliefs which enable hedge accounting to continue during the period of uncertainty before the replacement of an existing interest rate benchmark. In addition, the amendments require companies to provide additional information to investors about their hedging relationships which are directly affected by these uncertainties. The amendments did not have any impact on the financial position and performance of the Group as the Group does not have any interest rate hedge relationships.
- (c) Amendments to IFRS16 provides a practical expedient for lessees to elect not to apply lease modification accounting for rent concessions arising as a direct consequence of the covid-19 pandemic. The practical expedient applies only to rent concessions occurring as a direct consequence of the covid-19 pandemic and only if (i) the change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change; (ii) any reduction in lease payments affects only payments originally due on or before June 30, 2021; and (iii) there is no substantive change to other terms and conditions of the lease. The amendment is effective retrospectively for annual periods beginning on or after June 1, 2020 with earlier application permitted.

During the period ended June 30, 2020, no monthly lease payments for the leases of the Group's office buildings have been reduced or waived by the lessors as a result of the covid-19 pandemic and there are no other changes to the terms of the leases. The amendments did not have any impact on the financial position and performance of the Group.

- (d) Amendments to IAS 1 and IAS 8 provide a new definition of material. The new definition states that information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The amendments clarify that materiality will depend on the nature or magnitude of information. The amendments did not have any impact on the Group's interim condensed consolidated financial information.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

3. REVENUE AND OPERATING SEGMENT INFORMATION

Disaggregation of revenue

The following amounts represent revenue arising from providing research services under the three charge methods to third parties and investees of the Group. The investees of the Group include the associate, the joint venture and companies that the Group has investments in (carry in the condensed consolidated financial statements as financial assets at FVTPL).

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Revenue from services to non-investees:		
– Full-time-equivalent (“FTE”)	118,102	79,781
– Fee-for-service (“FFS”)	35,908	25,620
	154,010	105,401
Revenue from services to investees:		
– FTE	13,924	12,330
– FFS	867	270
– SFE	28,756	24,340
	43,547	36,940
	197,557	142,341

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

3. REVENUE AND OPERATING SEGMENT INFORMATION (continued)

Timing of revenue recognition

The following amounts represent revenue arising from providing research services over time and at a point in time:

Over time

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Revenue from FTE	132,026	92,111
Revenue from SFE	28,756	24,340
	160,782	116,451

At a point in time

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Revenue from FFS	36,775	25,890

For the purpose of resources allocation and performance assessment, the chief operating decision maker (i.e. the chief executive officer of the Group) reviews the overall results and financial position of the Group as a whole prepared based on the same accounting policies. Accordingly, the Group has only one single operating segment and no further analysis of this single segment is present.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

3. REVENUE AND OPERATING SEGMENT INFORMATION (continued)

Geographical Information

The Group's operation and non-current assets, excluding financial assets at FVTPL, contract assets and deferred tax assets, are mainly located in the People's Republic of China (the "PRC"). An analysis of the Group's revenue from external customers, analyzed by their respective country/region of operation, is detailed below:

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Revenue		
– United States of America	164,636	119,545
– PRC	26,989	22,135
– Europe	2,281	391
– Other Countries and Regions	3,651	270
	197,557	142,341

Information about major customers

Revenue from customers contributing over 10% of the total revenue of the Group during the reporting period is follows:

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Customer A	–	17,541

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

4. OTHER INCOME AND GAINS

	For the six months ended June 30,	
	2020 <i>RMB'000</i> (Unaudited)	2019 <i>RMB'000</i> (Unaudited)
Interest income		
– banks	7,748	6,919
– imputed interest income on rental deposits	103	76
Government grants and subsidies	3,567	1,718
Net foreign exchange gain	8,710	15,552
Gain on deemed disposal of interests in an associate	–	9,892
Gain on repurchase of convertible bonds (<i>Note 18</i>)	4,447	–
Gain on derivative financial instruments	1,421	–
Gain on disposal of right-of-use assets	1,145	–
Others	49	51
	27,190	34,208

5. FINANCE COSTS

	For the six months ended June 30,	
	2020 <i>RMB'000</i> (Unaudited)	2019 <i>RMB'000</i> (Unaudited)
Interest on convertible bonds	37,785	–
Interest on lease liabilities	731	811
Interest on bank loans	78	61
	38,594	872

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

6. (LOSS)/PROFIT BEFORE TAX

The Group's (loss)/profit before tax is arrived at after charging:

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Depreciation of property, plant and equipment	12,492	7,461
Depreciation of right-of-use assets	9,145	6,759
	21,637	14,220
Less: capitalized in contract costs	(532)	(969)
	21,105	13,251
Staff cost (including directors' emoluments):		
– Salaries and other benefits	77,215	54,914
– Retirement benefit scheme contributions	6,931	8,112
– Share-based payment expenses	2,360	4,323
	86,506	67,349
Less: capitalized in contract costs	(2,721)	(4,235)
	83,785	63,114
Auditors' remuneration	800	900
Lease payment in respect of short-term leases	1,376	1,534
Cost of inventories recognized as expenses	18,608	12,232

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

7. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The income tax expense of the Group for the period is analyzed as follows:

	For the six months ended June 30,	
	2020	2019
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Current tax:	5,983	8,823
Deferred tax:	1,896	3,837
	7,879	12,660

Pursuant to the relevant rules and regulations of the Cayman, the Company and the subsidiaries of the Group incorporated therein are not subject to any income tax in the Cayman.

Hong Kong profits tax has been provided at the rate of 16.5% (2019: 16.5%) on the estimated assessable profits arising in Hong Kong during the period, except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime. The first Hong Kong Dollars (“HK\$”) 2,000,000 (2019: HK\$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% and the remaining assessable profits are taxed at 16.5%.

The provision for Mainland China corporate income tax is based on the statutory rate of 25% of the assessable profits of certain Mainland China subsidiaries of the Group as determined in accordance with the Mainland China Corporate Income Tax Law which was approved and became effective on January 1, 2008, except for certain subsidiaries of the Group in Mainland China which are granted tax concession and are taxed at preferential tax rates.

Viva Biotech (Shanghai) Ltd. (“Viva Biotech Shanghai”) renewed its “High and New Technology Enterprise” qualification in 2019 and is entitled to the preferential tax rate of 15% from 2019 to 2021.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

8. (LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic (loss)/earnings per share amount is based on the (loss)/profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares in issue during the six months ended June 30, 2020 and 2019.

The weighted average number of ordinary shares for the purpose of calculating basic and diluted earnings per share for the six months ended June 30, 2019 has been retrospectively adjusted for the effect of the Share Split and the Capitalization Issue.

The diluted loss per share for the period ended June 30, 2020 did not assume conversion of the convertible bonds nor the exercise of Post-IPO Share Incentive Schemes as their inclusion would be anti-dilutive.

The calculations of the basic and diluted (loss)/earnings per share are based on:

	For the six months ended June 30,	
	2020	2019
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
(Loss)/earnings:		
(Loss)/profit attributable to equity holders of the parent, used in the basic and diluted (loss)/earnings per share	(530,272)	46,496

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

8. (LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (continued)

	Number of shares	
	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Unaudited)
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic (loss)/earnings per share calculation	1,407,166,209	1,211,632,627
Effect of dilutive potential ordinary shares:		
Pre-IPO Share Incentive Schemes of the Company	–	119,303,404
Weighted average number of ordinary shares for the purpose of calculating diluted earnings per share	1,407,166,209	1,330,936,031

9. DIVIDENDS

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Final declared – HK\$0.015 (2018: Nil) per ordinary shares (Note i)	23,037	–
Special dividend declared and paid	–	120,747

Notes:

- (i) On June 10, 2020, a final dividend of HK\$0.015 per ordinary share (in an aggregate amount of RMB23,037,000) was declared to shareholders of the Company whose names appeared on the Register of Members on June 19, 2020. The final dividend was paid on July 10, 2020.
- (ii) On August 31, 2020, an interim dividend of HK\$0.017 per ordinary share was declared to shareholders of the Company whose names appeared on the Register of Members on September 17, 2020.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

10. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT AND RIGHT-OF-USE ASSETS

During the six months ended June 30, 2020, the Group mainly acquired property, plant and equipment and right-of-use assets of approximately RMB70,235,000 and RMB125,010,000, respectively (six months ended June 30, 2019: RMB15,136,000 and RMB41,346,000 respectively), which including that: On March 9, 2020, Viva Biotech Shanghai acquired a 100% interest in Shanghai Shenyu Wires Co., Ltd. from two third-party individual owners at the consideration of RMB120,000,000, for the purpose to acquire property, plant and equipment and right-of-use assets of approximately RMB16,912,000 and RMB112,345,000, respectively. The newly acquired property, plant and equipment and right-of-use assets will be used for the expansion of research and development capacity and working area.

11. TRADE RECEIVABLES

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Trade receivables		
– related parties (<i>Note 20</i>)	220	1,987
– third parties	71,613	57,275
Allowance for impairment loss	(2,191)	(1,757)
	69,642	57,505

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Within 3 months	55,716	41,967
3 months to 1 year	10,393	12,145
1-2 years	3,533	3,393
	69,642	57,505

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

12. PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Other receivables		
– refundable deposits for potential acquisitions	30,000	70,000
– others	4,281	6,734
	34,281	76,734
Prepayments	2,312	1,302
Prepaid expenses	1,561	1,343
Value added tax recoverable	5,851	3,772
	9,724	6,417
Prepayments, other receivables and other assets	44,005	83,151

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

13. TRADE PAYABLES

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Trade payables – third parties	6,281	7,552

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Within 3 months	5,891	5,349
3 months to 1 year	91	1,188
1-2 years	299	1,015
	6,281	7,552

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

14. OTHER PAYABLES AND ACCRUALS

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Other payables – third parties	37,380	7,400
Accrued listing expenses and issue costs	251	251
Salary and bonus payables	20,824	20,052
Other taxes payable	578	691
Dividends payable	22,872	–
Interest payable	7,180	–
	89,085	28,394

15. FINANCIAL ASSETS AT FVTPL

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Unlisted investments at FVTPL	760,123	647,271
Financial products	95,652	5,212
	855,775	652,483
Analyzed for reporting purposes as:		
Current assets	95,652	29,629
Non-current assets	760,123	622,854
	855,775	652,483

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

15. FINANCIAL ASSETS AT FVTPL (continued)

At June 30, 2020, the financial products classified as financial assets at FVTPL represented unguaranteed financial products issued by banks, with no fixed maturity period and expected return rate from 3.60% to 3.75% per annum (at December 31, 2019: 2.9% per annum).

The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows:

	<i>RMB'000</i>
At January 1, 2019 (Audited)	204,740
Acquired	52,981
Recognized from SFE revenue	19,692
Recognized from deemed disposal of an associate	12,533
Gain on fair value change	48,168
At June 30, 2019 (Unaudited)	338,114
At December 31, 2019 (Audited)	647,271
Acquired	54,988
Recognized from SFE revenue	23,384
Gain on fair value change	54,676
Disposal	(24,472)
Exchange adjustment	4,276
At June 30, 2020 (Unaudited)	760,123

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

15. FINANCIAL ASSETS AT FVTPL (continued)

The movements in the carrying value of the financial products of FVTPL for the reporting period are as follows:

	<i>RMB'000</i>
At January 1 and June 30, 2019	–
At December 31, 2019 (Audited)	5,212
Acquired	2,659,853
Gain on fair value change	11,982
Disposal	(2,581,395)
At June 30, 2020 (Unaudited)	95,652

16. SHARE CAPITAL

	June 30, 2020 <i>RMB'000</i> (Unaudited)	December 31, 2019 <i>RMB'000</i> (Audited)
Issued and fully paid: 1,686,833,314 shares of US\$0.000025 each (December 31, 2019: 1,561,818,398 shares of US\$0.000025 each)	283	261

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

16. SHARE CAPITAL (continued)

A summary of movements in the Company's share capital is as follows:

	Number of shares in issue	Share capital <i>RMB'000</i>
At January 1, 2020 (audited)	1,561,818,398	261
Repurchased and cancelled of US\$0.000025 each	(3,652,500)	(1)
Exercise of share options of US\$0.000025 each (<i>Note 17</i>)	31,270,209	6
Conversion of convertible bonds of US\$0.000025 each (<i>Note 18</i>)	97,397,207	17
At June 30, 2020 (Unaudited)	1,686,833,314	283

17. SHARE OPTION SCHEMES

Details of the outstanding share options during the period are as follows:

Grant date	Number of options	Expiry date	Exercise price per share
January 2, 2018	1,125,000	January 1, 2028	US\$0.54
January 2, 2018	12,065,000	January 1, 2022	US\$0.54
June 21, 2018	500,000	June 20, 2022	US\$1.90

The Company's Pre-IPO Share Option Schemes (the "**Pre-IPO Schemes**") were adopted pursuant to resolutions passed on January 2, 2018 and June 21, 2018, respectively, for the primary purpose of providing incentives to the eligible employees of the Group.

The number of options and exercise price per share for the options granted on January 2, 2018 and June 21, 2018 represented the unadjusted number of options and exercise price before considering the Share Split and Capitalization Issue.

Grant date	Number of options	Expiry date	Exercise price per share
May 21, 2020	16,990,000	May 20, 2025	US\$0.98

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

17. SHARE OPTION SCHEMES (continued)

The Company's Post-IPO Share Option Scheme (the "Post-IPO Scheme") was adopted pursuant to the resolutions passed on May 21, 2020, for the primary purpose of providing incentives to the eligible employees of the Group. Under the Post-IPO Scheme, 16,990,000 share options were granted during the period (2019: Nil).

The Group recognized the total expense of RMB2,360,000 for the six months ended June 30, 2020 in relation to share options granted by the Company (six months ended June 30, 2019: RMB4,323,000).

The following share options were outstanding during the period:

	For the six months ended June 30,			
	2020		2019	
	Weighted average exercise price <i>US\$ per share</i>	Number of options	Weighted average exercise price <i>US\$ per share</i>	Number of options
At January 1	0.13	59,121,313	0.26	33,885,000
Share Split and Capitalization Issue	–	–	0.08	114,839,968
Granted during the period	0.98	16,990,000	–	–
Forfeited during the period	0.98	(60,000)	–	–
Exercised during the period	0.14	(31,270,209)	0.01	(88,901,398)
At June 30	0.45	44,781,104	0.13	59,823,570

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

17. SHARE OPTION SCHEMES (continued)

The exercise prices and exercise periods of the share options outstanding as at the end of the reporting period are as follows:

At June 30, 2020 Number of options (Note)	Exercise price US\$ per share (Note)	Exercise period
4,285,967	0.12	January 1, 2020 ~ January 1, 2028
23,565,137	0.12	January 1, 2020 ~ January 1, 2022
16,930,000	0.98	May 21, 2021 ~ May 20, 2025
44,781,104		

At June 30, 2019 Number of options (Note)	Exercise price US\$ per share (Note)	Exercise period
2,194,555	0.43	May 9, 2019 ~ June 20, 2020
4,937,748	0.12	January 1, 2020 ~ January 1, 2028
52,691,267	0.12	January 1, 2020 ~ January 1, 2022
59,823,570		

Note: The number of options and exercise price per share represented the adjusted number of options and exercise price after considering the Share Split and Capitalization Issue.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

17. SHARE OPTION SCHEMES (continued)

The fair value of equity-settled share options granted during the period was estimated as at the date of grant, using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:

	For the six months ended June 30, 2020
Dividend yield (%)	0.26
Expected volatility (%)	38.10
Risk-free interest rate (%)	0.36
Expected life of options (year)	5.00
Weighted average share price (HK\$ per share)	2.38

The volatility measured at the standard deviation of expected share price returns is based on statistical analysis of comparable listed companies in the same industry.

At the end of reporting period, the Company had 44,781,104 share options outstanding under the Schemes. The exercise in full of the outstanding share options would, under the present capital structure of the Company, result in the issue of 44,781,104 additional ordinary shares of the Company, an additional share capital of approximately US\$1,000 and a share premium of approximately US\$20,049,000 (before issue expenses).

18. CONVERTIBLE BONDS

On February 11, 2020, Viva Incubator Investment Management Limited (“**Viva Incubator HK**”), an indirectly wholly-owned subsidiary of the Company, issued a five-year 2.5% convertible bonds in an aggregate principal amount of US\$180,000,000, which was guaranteed by the Company.

The conversion period is on or after March 23, 2020 up to the close of business on the 10th day prior to February 11, 2025 (the “**maturity date**”) and the price of ordinary shares of the Company to be issued in exercise of the right of conversion is initially HK\$5.7456 per share. The conversion price would be subjected to adjustment for, among other things, consolidation, subdivision, redesignation or reclassification of shares, capitalization of profits or reserves, distributions, rights issues of shares or options over shares, rights issues of other securities, issues at less than current market price, modification of rights of conversion, other offers to shareholders.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

18. CONVERTIBLE BONDS (continued)

In addition to the conversion price adjustment situation mentioned above, on February 11, 2021 and February 11, 2022 (the “reset date”), the conversion price shall be adjusted by the arithmetic average of the volume weighted average prices of the shares on each trading day for the period of 20 consecutive trading days ending on the trading day immediately prior to the relevant reset date. Any such adjustment to the conversion price shall be limited such that the adjusted conversion price in no event shall be less than HK\$4.56.

On the maturity date, Viva Incubator HK would redeem all unconverted bonds from bondholders at the price of 108.21% of its principal amount, together with accrued and unpaid interest thereon.

On February 11, 2023, the bondholders would have the right to ask Viva Incubator HK to redeem all or some of bonds at 104.73% of its principal amount, together with interest accrued but unpaid to (but excluding) such date.

On giving not less than 30 nor more than 60 days’ notice to the bondholders, the trustee and the principal agent (which notice will be irrevocable), Viva Incubator HK may at any time prior to the maturity date redeem in whole, but not in part, the bonds for the time being outstanding at their early redemption amount, together with interest accrued but unpaid to (but excluding) the date fixed for redemption provided that prior to the date of such notice at least 90% in principal amount of the bonds originally issued has already been converted, redeemed or purchased and cancelled.

The convertible bonds comprise two components:

- (a) was initially measured at fair value amounting to US\$129,863,000 (equivalent to RMB919,365,000). It is subsequently measured at amortized cost using the effective interest method after considering the effect of the transaction costs.
- (b) Derivative component comprises conversion options and early redemption options (not closely related to the debt component), which were initially measured at fair value amounting to US\$50,137,000 (equivalent to RMB354,945,000) and subsequently measured at fair value with changes in fair value recognized in profit or loss.

The total transaction costs of US\$2,588,000 (equivalent to RMB18,284,000) that are related to the issue of the convertible bonds were allocated to the debt and derivative components in proportion to their respective fair values.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

18. CONVERTIBLE BONDS (continued)

The total transaction costs relating to the derivative component were charged to profit or loss during the period. Transaction costs relating to the debt component were included in the carrying amount of the debt portion and amortized over the period of the convertible bonds using the effective interest method.

	Debt Component	Embedded derivative components	Total
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Issue of convertible bonds	919,365	354,945	1,274,310
Transaction costs	(13,216)	(5,068)	(18,284)
Transaction costs charged into profit or loss			
immediately	–	5,068	5,068
Exchange adjustments	1,217	(5,158)	(3,941)
Interest charged	26,289	–	26,289
Repurchase (<i>Note i</i>)	(22,981)	(8,874)	(31,855)
Conversion (<i>Note ii</i>)	(373,040)	(269,396)	(642,436)
Loss arising on changes of fair value	–	615,526	615,526
At June 30, 2020	537,634	687,043	1,224,677

Notes:

- (i) On April 16, 2020, an aggregate principal amount of US\$4,500,000 convertible bonds were repurchased by Viva Incubator HK at a total consideration of US\$3,870,000 (equivalent to RMB31,855,000), with a gain on repurchase of convertible bonds of US\$630,000 (equivalent to RMB4,447,000) recognized.
- (ii) Up to June 30, 2020, an aggregate principal amount of US\$72,000,000 convertible bonds were converted into 97,397,207 ordinary shares.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

19. CAPITAL COMMITMENTS

The Group had capital commitments under non-cancellable contracts as follows:

	June 30, 2020 RMB'000 (Unaudited)	December 31, 2019 RMB'000 (Audited)
Commitment for:		
the acquisition of property, plant and equipment	323,900	343,789
the unlisted equity investments at FVTPL	58,760	11,214
	382,660	355,003

20. RELATED PARTY TRANSACTIONS

(1) Names and relationships with related parties

The following companies are significant related parties of the Group that had transactions and/or balances with the Group during the periods presented in the condensed consolidated financial statements.

Company	Relationship
Jiaying Tekeluo Biotech Co., Ltd.	Associate
Jiaying Youbo Biotech Co., Ltd.	Joint Venture
QureBio Limited (<i>Note</i>)	Associate

Note: Since March 14, 2019, QureBio Limited is no longer a related party of the Group.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

20. RELATED PARTY TRANSACTIONS (continued)

(2) Transactions with related parties

Provision of research and development services

	For the six months ended June 30,	
	2020	2019
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Jiaxing Tekeluo Biotech Co., Ltd.	482	1,274
Jiaxing Youbo Biotech Co., Ltd.	2,791	2,066
QureBio Limited	–	654
	3,273	3,994

(3) Related party balances

	June 30,	December 31,
	2020	2019
	RMB'000	RMB'000
	(Unaudited)	(Audited)
Trade receivables from related parties		
Jiaxing Tekeluo Biotech Co., Ltd.	135	174
Jiaxing Youbo Biotech Co., Ltd.	85	1,813
	220	1,987

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

20. RELATED PARTY TRANSACTIONS (continued)

(4) Compensation of key management personnel of the Group

	For the six months ended June 30,	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Director fee	821	252
Salaries and other benefits	5,781	4,375
Performance-based bonus	66	234
Retirement benefits scheme contributions	25	45
Share-based compensation	268	2,198
	6,961	7,104

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follow:

	Carrying amounts		Fair values	
	At June 30, 2020 RMB'000 (Unaudited)	At December 31, 2019 RMB'000 (Audited)	At June 30, 2020 RMB'000 (Unaudited)	At December 31, 2019 RMB'000 (Audited)
Financial assets				
Cash and cash equivalents	1,521,285	904,091	1,521,285	904,091
Restricted bank balances	71,614	5,908	71,614	5,908
Trade receivables	69,642	57,505	69,642	57,505
Time deposits with original maturity of over three months	355,933	–	355,933	–
Prepayments, other receivables and other assets	31,469	72,061	31,469	72,061
Rental deposits	7,566	2,844	7,566	2,844
Financial assets at fair value through profit or loss	855,775	652,483	855,775	652,483
Financial liabilities				
Derivative financial instruments	503	–	503	–
Trade payables	6,281	7,552	6,281	7,552
Other payables and accruals	66,407	6,507	66,407	6,507
Interest-bearing bank borrowings	16,969	1,865	16,969	1,865
Lease liabilities	20,109	47,542	20,109	47,542
Convertible bonds – debt component	537,634	–	537,634	–
Convertible bonds – embedded derivative instruments	687,043	–	687,043	–

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The Group's financial assets and financial liabilities at FVTPL which are measured at fair value (details refer to Notes 15 and 18) at June 30, 2020 and December 31, 2019 are grouped under Level 2 and Level 3 hierarchy. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular the valuation techniques and inputs used).

Financial instruments

	Valuation techniques and key inputs	Significant unobservable inputs	Relationship of unobservable inputs to fair value
Financial assets			
Financial products	Discounted cash flow method	N/A	N/A
Unlisted investment at FVTPL	Most recent transaction price	N/A	N/A
	Comparable company method	The ratio of P/R&D	The higher the ratio of P/R&D, the higher the valuation.
	Backsolve from most recent transaction price	IPO probability	The higher the probability, the higher the valuation.
	Discounted cash flow method	Conversion probability	The higher the probability, the higher the valuation.
Financial liabilities			
Derivative financial instruments	Discounted cash flow method	N/A	N/A
Convertible bonds – embedded derivative components	Binominal option pricing model	Expected volatility	The higher the expected volatility, the higher the valuation.
		Risk-free rate	The lower risk-free rate, the higher the valuation.

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at June 30, 2020

	Fair value measurement using			Total <i>RMB'000</i> (Unaudited)
	Quoted prices in active markets (Level 1) <i>RMB'000</i> (Unaudited)	Significant observable inputs (Level 2) <i>RMB'000</i> (Unaudited)	Significant unobservable inputs (Level 3) <i>RMB'000</i> (Unaudited)	
Financial products	–	95,652	–	95,652
Unlisted investment at FVTPL	–	113,305	646,818	760,123
	–	208,957	646,818	855,775

As at December 31, 2019

	Fair value measurement using			Total <i>RMB'000</i> (Audited)
	Quoted prices in active markets (Level 1) <i>RMB'000</i> (Audited)	Significant observable inputs (Level 2) <i>RMB'000</i> (Audited)	Significant unobservable inputs (Level 3) <i>RMB'000</i> (Audited)	
Financial products	–	5,212	–	5,212
Unlisted investment at FVTPL	–	334,529	312,742	647,271
	–	339,741	312,742	652,483

Notes to the Interim Condensed Consolidated Financial Information

June 30, 2020

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy (continued)

Liabilities measured at fair value:

As at June 30, 2020

	Fair value measurement using			Total <i>RMB'000</i> (Unaudited)
	Quoted prices in active markets (Level 1) <i>RMB'000</i> (Unaudited)	Significant observable inputs (Level 2) <i>RMB'000</i> (Unaudited)	Significant unobservable inputs (Level 3) <i>RMB'000</i> (Unaudited)	
Derivative financial instruments	–	503	–	503
Convertible bonds – embedded derivative component	–	–	687,043	687,043
	–	503	687,043	687,546

The Group did not have any financial liabilities measured at fair value as at December 31, 2019.

22. SUBSEQUENT EVENTS

Except as disclosed elsewhere of the consolidated financial information, the Group has the following significant events subsequent to June 30, 2020:

- a. On July 1, 2020, the Company announced that Viva Biotech Shanghai had successfully entered into a bid for the land use right of the property by way of internet auction through taobao.com (淘寶網) published by the Shanghai Pudong District People's Court (上海市浦東新區人民法院) at a bidding price of RMB392,370,000 and obtained the internet auction confirmation on the same day. The Company expects that the acquisition of the property will provide operating space to meet the Group's business growth and development in the coming years.
- b. On July 10, 2020, an aggregate of 130,000,000 placing shares were placed at the placing price of HK\$8.15 per placing share, representing 7.07% of the issued share capital of the Company as enlarged by the allotment and issued of the placing shares immediately upon completion of the placing. The net proceeds from the placing, after deduction of the placing commission and other related expenses, amounted to approximately HK\$1,050,730,000 (equivalent to RMB948,263,000).
- c. On August 8, 2020, Viva Biotech Shanghai entered into the share purchase agreement pursuant to which Viva Biotech Shanghai agreed to acquire 80% of the equity interest in Zhejiang Langhua Pharmaceutical Co., Ltd., at the consideration of RMB2,560,000,000, which will be satisfied by cash.

Definitions

In this interim report, unless the context otherwise requires, the following expressions shall have the following meanings.

“Audit Committee”	the audit committee of the Board
“Board of Directors” or “Board”	the board of Directors
“BVI”	British Virgin Islands
“CG Code”	the “Corporate Governance Code” as contained in Appendix 14 to the Listing Rules
“China” or “PRC”	the People’s Republic of China, which, for the purpose of this interim report and for geographical reference only, excludes Hong Kong, Macau and Taiwan
“China Finance Strategies”	China Finance Strategies Investment DB Limited, a company incorporated in the BVI on December 15, 2006, which is wholly owned by Mr. Hua
“Company”, “our Company”	Viva Biotech Holdings (维亚生物科技控股集团), an exempted company with limited liability incorporated in the Cayman Islands on August 27, 2008
“Controlling Shareholder(s)”	has the meaning ascribed to it under the Listing Rules and, unless the context requires otherwise, refers to Mr. Mao and Concord Trust Company, LLC
“Director(s)”	the director(s) of the Company or any one of them
“Fenghe Harvest”	Fenghe Harvest Ltd, a company incorporated in the BVI on July 1, 2014, which is wholly-owned by Mr. John Wu Jiong, our substantial Shareholder
“Global Offering”	has the meaning ascribed to it under the Prospectus
“Group”, “our Group”, “we” or “us”	the Company and its subsidiaries from time to time or, where the context so requires, in respect of the period prior to our Company becoming the holding company of its present subsidiaries, such subsidiaries as if they were subsidiaries of our Company at the relevant time
“HK\$” or “Hong Kong dollars”	Hong Kong dollars and cents, each being the lawful currency of Hong Kong

Definitions

“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“IFRS”	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
“Listing”	the listing of the Shares on the Main Board of the Stock Exchange
“Listing Date”	May 9, 2019, on which the Shares were listed and from which dealings therein were permitted to take place on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)
“Mao and Sons”	Mao and Sons Limited, a company incorporated in the BVI on January 23, 2018, which is indirectly wholly owned by the trustee of the Z&M Trust, a revocable family trust set up by Ms. Mao as settlor and protector
“Model Code”	the “Model Code for Securities Transactions by Directors of Listed Issuers” set out in Appendix 10 to the Listing Rules
“Mr. Hua”	Mr. Hua Fengmao, one of our founders, the chief financial officer and executive Director of the Company
“Mr. Mao”	Mr. Mao Chen Cheney, one of our founders, the Chairman and chief executive officer of the Company
“Ms. Mao”	Ms. Mao Jun, a non-executive Director of the Company and the sister of Mr. Mao
“Pre-IPO Share Incentive Schemes”	the 2009 Stock Incentive Plan, the 2018 Stock Incentive Plan and the Pre-IPO Stock Incentive Plan, the principal terms of which are summarized in “Statutory and General Information – D. Share Incentive Schemes – 1. Pre-IPO Share Incentive Schemes” in Appendix IV to the Prospectus
“Pre-IPO Stock Incentive Plan”	the pre-IPO stock incentive plan approved and adopted by the Company on June 21, 2018, the principal terms of which are summarized in “Statutory and General Information – D. Share Incentive Schemes – 1. Pre-IPO Share Incentive Schemes” in Appendix IV to the Prospectus

Definitions

“Prospectus”	the prospectus of the Company dated April 25, 2019
“Reporting Period”	the six months ended June 30, 2020
“Restricted Share Unit Scheme”	the restricted share unit scheme approved by the Company on June 5, 2020, the principal terms of which are summarized in the Company’s announcement on the same date
“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Share(s)”	ordinary share(s) in the share capital of our Company with a par value of US\$0.000025 each
“Shareholder(s)”	holder(s) of Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“US\$” or “United States dollars”	United States dollars and cents, each being the lawful currency of United States of America
“Wu and Sons”	Wu and Sons Limited, a company incorporated in the BVI on January 23, 2018, which is wholly owned by Mr. John Wu Jiong, our substantial Shareholder
“Zhang and Sons”	Zhang and Sons Limited, a company incorporated in the BVI on January 23, 2018, which is indirectly wholly owned by the trustee of the Z&M Trust, a revocable family trust set up by Ms. Mao as settlor and protector
“%”	per cent
“2009 Stock Incentive Plan”	The stock incentive plan approved and adopted by the Company on July 1, 2009 and as amended and restated on June 8, 2018
“2018 Stock Incentive Plan”	The stock incentive plan approved and adopted by the Company on January 1, 2018 and as amended and restated on June 8, 2018